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ABSTRACT 
COMPUTATIONAL MODELING OF PROTEIN KINASES:  
MOLECULAR BASIS FOR INHIBITION AND CATALYSIS 
Yingting Liu 
Ravi Radhakrishnan 
Protein kinases catalyze protein phosphorylation reactions, i.e. the transfer of the γ-
phosphoryl group of ATP to tyrosine, serine and threonine residues of protein substrates. 
This phosphorylation plays an important role in regulating various cellular processes. 
Deregulation of many kinases is directly linked to cancer development and the protein 
kinase family is one of the most important targets in current cancer therapy regimens. 
This relevance to disease has stimulated intensive efforts in the biomedical research 
community to understand their catalytic mechanisms, discern their cellular functions, and 
discover inhibitors. With the advantage of being able to simultaneously define structural 
as well as dynamic properties for complex systems, computational studies at the atomic 
level has been recognized as a powerful complement to experimental studies. In this 
work, we employed a suite of computational and molecular simulation methods to (1) 
explore the catalytic mechanism of a particular protein kinase, namely, epidermal growth 
factor receptor (EGFR); (2) study the interaction between EGFR and one of its inhibitors, 
namely erlotinib (Tarceva); (3) discern the effects of molecular alterations (somatic 
mutations) of EGFR to differential downstream signaling response; and (4) model the 
interactions of a novel class of kinase inhibitors with a common ruthenium based 
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organometallic scaffold with different protein kinases. Our simulations established some 
important molecular rules in operation in the contexts of inhibitor-binding, substrate-
recognition, catalytic landscapes, and signaling in the EGFR tyrosine kinase. Our results 
also shed insights on the mechanisms of inhibition and phosphorylation commonly 
employed by many kinases.  
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Chapter 1 Introduction 
1.1 Overview 
Most protein kinases reported have been found to share a very similar structure fold, 
implicating an overall similarity in their mechanism of enzymatic action. However, as 
protein kinases control many different signaling pathways, the details of how they are 
regulated and how they recognize and subsequently regulate their substrates are found to 
be different. In this work, we focused on a biologically and pharmaceutically important 
protein kinase, namely the epidermal growth factor receptor (EGFR) tyrosine kinase 
domain (TKD). We employed a suite of molecular and multiscale simulation methods to 
investigate mechanisms of substrate recognition and catalysis in EGFR (Chapter 2), the 
interaction between EGFR and a small molecule inhibitor (Chapter 3), and the EGFR 
signaling network (Chapter 4). We investigated the unique properties of this kinase and 
also identified additional conserved properties applicable to homologous kinases. In 
chapter 5, we developed and employed a computational protocol to predict the binding of 
a novel ruthenium based inhibitors to different protein kinases to understand the 
selectivity profile of the new inhibitor scaffold.  
1.2 Biological background on protein kinases 
Protein kinases, one of the most important targets in the current cancer therapy, are the 
largest enzyme family involved in cell signal transduction [24, 124]. They are encoded by 
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approximately 2% of eukaryotic genes and more than 500 protein kinases are identified 
based on the human genome sequencing [168] and biochemical studies. Protein kinases 
catalyze the transfer of the  -phosphate group from an ATP molecule to tyrosine, serine 
or threonine residues in proteins. This process plays an essential role in regulating many 
fundamental cellular processes [138].  Constitutive or inappropriate activation of protein 
kinases are seen in a variety of cancers and small molecule inhibitors are designed to 
target/inhibit kinase signaling in such scenarios [61]. Understanding the inhibition and 
phosphorylation of protein kinases are significant to guide cancer therapy. Kinases 
studied in this work, namely EGFR (our main focus) and other members in the ErbB 
family, GSK3-β, CDK2, and PIM1 are all well-established drug targets. The following 
sections will describe the background on protein kinases using the EGFR protein kinase 
as a template.  
1.2.1 Protein kinases play key roles in cellular signaling 
Protein kinases play important roles on cellular signaling. A typical example is the ErbB-
mediated signaling network.  
The ErbB family of receptors have received much attention, given their strong 
association with malignant proliferation [125]. The family has four members ― the 
epidermal growth factor receptor (EGFR or ErbB1 or HER1), ErbB2 (or HER2), ErbB3, 
and ErbB4. They activate a multi-layered network mediating crucial pathways, including 
Ras-Raf-MAP-kinase, PI3K-Akt, and STAT,  leading to cell proliferation, differentiation, 
migration and metabolism [63, 120, 218, 281] (Figure 1.1). Over-expression or 
mutational modification of the ErbB family are often implicated in a large percentage of 
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clinical cancers of various types [173, 233]. They, especially EGFR and ErbB2, have 
already been established as targets in cancer therapy. Small molecule inhibitors for EGFR 
are of significant interest as cancer therapeutic drugs [61]. A better understanding of 
these receptors is critical to discern the cancer mechanism and will help to design 
efficacious drugs.  
 
Figure 1.1 ErbB family signaling network [281]. 
The ErbB receptors share a common protein structure characterized by an extracellular 
region (serves as the ligand binding domain), a transmembrane domain, and an 
intracellular tyrosine kinase domain (the focus of this work) flanked by a juxtamembrane 
and a C-terminal regulatory region [63, 158]. In the presence of activating ligands, 
namely, the epidermal growth factor (EGF), transforming growth factor- (TGF-), and 
several other peptide growth factors [63], the family members associate to form 
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homo/hetero dimers, activating their intracellular tyrosine kinases using an unique 
allosteric mechanism [289], followed by phosphorylation of several tyrosine residues in 
the C-terminal tails. The phosphorylated tyrosines in the C-tails serve as docking sites for 
SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains of signaling 
proteins, leading to activation of proteins involved downstream in the signaling cascades.  
1.2.2 Active and inactive structures of protein kinases 
A significant amount of work has been dedicated to characterizing the function of protein 
kinases. A fast expanding structural database is continuing to provide valuable insights 
into the molecular details of kinase function and regulation. It has been well established 
that most protein kinases are highly conversed in both sequence and structures [5]. Owing 
to the highly conserved nature of the core structure, a description of EGFR tyrosine 
kinase domain (TKD), a typical protein kinase, in this thesis will encompasses the main 
features of all members of the kinase family.  
Similar to most protein kinases, EGFR TKD shares a two-lobed structural fold, an N-
terminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe) (Figure 1.2). The two 
domains, connected by a small linker region, form a binding pocket for ATP and the 
substrate. Several conserved components near the site of phosphoryl transfer play 
important catalytic functions, including the glycine-rich loop (G-loop) and αC-helix in N-
lobe, as well as the activation loop (A-loop) and catalytic loop (C-loop) in the C-lobe.  
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Figure 1.2 Key components of EGFR TK (PDBID: 2GS6 [288]). 
Like many other kinases, two EGFR TKD conformations, namely active and inactive, 
have been captured by crystallography [248, 276, 284, 288]. The active EGFR TKD was 
solved both as an apo-kinase (i.e. in isolation) and in  the presence of inhibitors, including 
erlotinib and gefitinib [248, 284], while the inactive EGFR TKD was crystallized by 
mutating a residue critical destabilizing the activating dimer interface or in complex with 
a bulky inhibitor, lapatinib. The most notable structural difference between active and 
inactive structure of the EGFR TKD is the outward rotation of the αC-helix and the 
conformational change of activation loop (Figure 1.3). In a fully active state, the A-loop 
adopts an open conformation so that it is positioned away from the catalytic center, 
providing a platform for substrate binding [248] (shown in Figure 1.2). The side chain of 
the aspartate (Asp831) in the DFG motif is directed into the ATP binding site, which is 
required to coordinate Mg
2+
 and to help orient the  -phosphate group of ATP for 
efficient phosphoryl transfer [248, 289]. The αC-helix is positioned toward the catalytic 
core, as a result, the catalytic glutamate residue (Glu738) located nearly at the center of 
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αC-helix bridges a lysine residue (Lys721), conserved across several kinases, which is 
important in positioning the phosphates of ATP. In contrast, the inactive state is 
characterized by an outward shifting of the αC-helix and a closed conformation of the 
activation loop.  The shift of αC-helix in the inactive EGFR TKD results in the loss of the 
Glu-Lys salt bridge and makes the pocket between the two lobes larger, which 
accommodate the extra fluorobenzyl-oxy moiety of lapatinib (Figure 1.3).  
1.2.3 Protein kinase substrate recognition 
 
Figure 1.3 Active and inactive form of EGFR TKD. Blue: inactive and red: active.  
Protein kinases regulate several essential signaling pathways by recognizing [225, 255], 
recruiting and phosphorylating a variety of  substrates. Protein kinases poorly 
phosphorylate free amino acids and it is believed that the affinity and specificity of 
signaling cascades are in-part determined by the sequence identity of phospho-tyrosines 
on substrates [226]. That is, the specificity in-part depends on how the kinase recognizes 
the local sequence of substrate proteins at the P-site (shown in Figure 1.2), i.e., the amino 
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acids situated immediately proximal to the P-site [142, 261]; the nomenclature for these 
resides are P-1, P-2, P-3, etc., for those N-terminal to the P-site, and P+1, P+2, P+3, etc., 
for those C-terminal to the P-site. Experience has suggested that different kinases show 
preference for substrates with particular amino acid at the positions close to the P-site 
[28, 40, 43, 104]. EGFR TKD, for example, shows preference for substrates with 
glutamic acid at the P-1 position and large hydrophobic amino acids at the P+1 position 
[118, 123, 149, 245]. The precise relationship of such a sequence identity to substrate 
specificity and the catalytic mechanism is still not understood.  
Besides the local sequences flanking the P-site, there are many factors influence substrate 
specificity of particular protein kinases. For example, CDK2 uses a hydrophobic patch, 
RXL, to help recruit its substrate p107, which locates about 40Å away from the site of 
phosphoryl transfer [225].  
1.2.4 Protein kinase catalytic mechanism 
Protein kinases deliver a single phosphoryl group from the gamma position of ATP to the 
hydroxyls of serine, threonine, and tyrosine in protein substrates. Extensive efforts have 
been made to understand the details of this phosphoryl transfer reaction. The cAMP-
dependent protein kinase (PKA) is by far the best understood protein kinase from this 
point of view [167] and substantial progress has also been made with other kinases  [16, 
17, 30, 41]. Although several details are yet to be resolved, a common mechanism 
believed to be in operation among kinases can be defined:  
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1) Mg2+ ions are involved in the reaction. One Mg2+ ion is believed to be essential for 
catalysis [5]. This metal ion is chelated Mg
2+
 by the phosphates of ATP and one 
conserved aspartic acid (as observed in the crystallographic structure of PKA, 
PDBID:1ATP) [167, 256, 292]. A second metal ion is also observed in the active site 
of some enzymes when the crystal is soaked with high concentration of Mg
2+
 ions. 
The coordination of this metal varies among the different structures available [5].  
 
Figure 1.4 Stereo view of Mg2ADP, AIF3, SP20 (substrate serine), and catalytically important residues in 
the catalytic subunit of cAMP-dependent protein kinase.  
2) In phosphoryl-transfer by kinases and polymerases, nucleophilic attack on the target 
phosphate proceeds via a conformation that resembles a trigonal-bipyramidal 
transition state [154, 249], shown in Figure 1.4. 
3) The phosphoryl-transfer can occur through either an associative or a dissociative 
mechanism [64] (showed in Figure 1.5). In the dissociative mechanism, the cleavage 
of the bond between the phosphorus center and the leaving group oxygen precedes 
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the bond formation with the attacking nucleophile. On the contrary, in associative 
mechanism, the bond formation between the attacking nucleophile and the 
phosphorus center precedes the bond cleavage. Although it is well accepted that the 
dissociative mechanism is the preferred mechanism for reaction in solution for 
monoester [29, 145, 175, 220, 292] which are particularly relevant for the reaction 
catalyzed by protein kinases, discerning the transition state of protein kinase 
catalyzed reaction is complex, resulting in controversial experimental interpretations 
[145, 167, 294].  
 
Figure 1.5 Dissociative vs. associative mechanisms for phosphoryl transfer [5]. 
4) The potential roles of specific residues around catalytic site are still not clearly 
understood. There is a debate over  the role of the conserved aspartic residue (D813  
in EGFR or D166 in PKA) in the catalytic loop [160]. This conserved aspartate is 
clearly important for efficient catalysis. Replacement of this residue with alanine in 
PKA and PhK results in decrease in kcat by 2-4 orders of magnitude [100, 241].  
However, the potential function of this conserved residue is ardently debated. The 
facts that in PKA as well as in other kinases, the aspartate (D166 in PKA) forms a 
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hydrogen bond with the substrate peptide and that the second-order rate constant, 
kcat/Km, for the phosphorylation of peptides is pH sensitive, support a general-base 
mechanism [282]. However, it is also shown that high negative charge on the 
hydroxyl could inhibit the reaction if charge repulsion with the γ phosphate is 
considered [145], which limits the advantage of a general base reaction mechanism. 
Another proposal is that the carboxyl group may position the hydroxyl for productive 
attack of the γ phosphate of the ATP and the proton would not be transferred to the 
aspartate. Computational modeling methods may serve to further clear this debate.  
1.2.5 Pharmacophore model of kinases and ATP-competitive inhibitors  
 
Figure 1.6 Pharmacophore model of the ATP-binding site of protein kinases. ATP is in red. Sug1, Hyp1, 
and Hyc1, Hin are residues lining the sugar region (Sug), hydrophobic pocket (Hyp), hydrophobic channel 
(Huc) and the hinge region respectively [82].  
Protein kinases have been identified as one of the most important targets in the current 
cancer therapy. One of ways to inhibit abnormal kinase activity is to design small 
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molecule inhibitors to bind into the ATP binding cleft, block ATP binding and therefore 
inhibit the phosphorylation. The success of small-molecule ATP-competitive inhibitors 
such as imatinib (Gleevec) for the treatment of chronic myeloid leukemia (CML) and 
gastrointestinal stromal tumors (GIST) confirmed that this strategy is indeed effective 
[42]. In spite of the success of Gleevec, the design of ATP-competitive inhibitors that are 
selective (specific) for a particular kinase appears to be quite challenging due to the 
conserved nature of protein structures.  
X-ray crystal structures for a range of kinases are available in the Protein Data Bank 
(PDB), which provide structural basis for understanding kinase inhibition and facilitate 
structure-guided design of kinase-specific inhibitors. The catalytic clefts of protein 
kinases usually include two hydrophobic pockets (Hyp1 and Hyc1), adenine region, 
„sugar‟ pocket and the phosphate groove, shown in Figure 1.6. The adenine region 
contains the two key hydrogen bonds formed by the interaction of the N-1 and N-6 amino 
groups of the adenine ring with the backbone NH and carbonyl groups of the adenine 
anchoring hinge region (Met769 in EGFR) of the protein kinase. Many potent inhibitors 
use at least one of these hydrogen bonds. The hydrophobic pocket is not used by ATP, 
but is exploited in the design of most kinase inhibitors. It plays an important role for 
inhibitor selectivity, and its size is different in active and inactive kinase states. The 
hydrophobic channel opens to solvent and is not used by ATP and hence, it can be 
exploited in the design of inhibitors. The phosphate binding region offers little 
opportunity in terms of inhibitor binding affinity due to high solvent exposure. However, 
it can be utilized in improving selectivity.  
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1.3 Computational methods and their applications in biological 
studies 
Besides the chemical approaches, computational methods (described below) are also 
widely used to understand the inhibition and phosphorylation mechanism of protein 
kinases.  
1.3.1 Molecular dynamics (MD) simulations 
Empirical force field-based molecular dynamics (MD) simulations [19] are widely 
applied to refine molecular structures, obtain information on the time evolution of 
conformations that is otherwise elusive. Along with a range of complementary 
computational approaches, MD simulations have the ability to analyze the relationship of 
structures to energies, which experimental approaches can only access indirectly, and 
thus have become invaluable for structure/function analyses in proteins.  
To perform MD simulations, the starting point is defining the initial coordinates and 
initial velocities of the atoms characterizing the model system, for example, the desired 
biomolecule plus the biologically relevant environment; i.e. water molecules or other 
solvent and/or membranes.  The coordinates of the desired biomolecule can usually be 
found as structural data (X-ray or NMR) deposited into the protein data bank (PDB); 
otherwise it is possible to derive initial geometry and coordinate data from model 
building techniques, including homology methods. This step also typically includes the 
placement and positioning of the environment of the molecules (solvation, ionic strength 
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etc.).  The initial velocities are typically derived from the Maxwell-Boltzmann 
distributions at the desired temperature of the simulation. The potential of interactions of 
each of the atoms are calculated using a force field, which parameterizes the non-bonded 
and bonded interaction terms of each atom depending on its constituent atom 
connectivity: bond terms, angle terms, dihedral terms, improper dihedral terms, non-
bonded Lennard-Jones terms, and electrostatic terms.  The potential interactions are 
summed across all the atoms contained in the system, to compute an overall potential 
energy function for the system [103]: 
               
     
           
      
           
         
  
     
       
  
   
   
   
 
  
  
   
   
   
 
 
   
    
    
       
 
Taking the derivative of the potential energy function yields the force, and from 
Newton‟s second law, this is equal to mass times acceleration. Although, the process 
seems simple, the derivative function results in a set of 3N-coupled 2
nd
 order ordinary 
differential equations that must be solved numerically.  The solution consists of a 
numerical recipe to advance the positions and the velocities by one time step.  This 
process is repeated over and over again to generate MD trajectories of constant energy. 
Constant temperature dynamics are derived by coupling the system to a thermostat using 
well established formulations such as the Langevin dynamics or the Nose-Hoover 
methodologies [37].  Application of MD simulations to biomolecules is facilitated by 
several popular choices of force fields such as  CHARMM27 [271] (www.charmm.org), 
AMBER [227] (www.ambermd.org), and GROMOS[192] (www.gromacs.org), as well as 
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dynamic simulations packages and visualization/analysis tools such as NAMD [122] 
(www.ks.uiuc.edu/Research/namd/) and VMD [206] (www.ks.uiuc.edu/Research/vmd/).  
With analysis of molecular dynamics trajectories, it is possible to calculate statistical 
properties under a variety of initial and other external conditions [162] such as hydrogen 
bond analyses for hydrophilic interactions and solvent accessible surface area for 
hydrophobic interactions.  For example, by analyzing the relative positions of the 
hydrogen bond donors to the hydrogen bond acceptors with a preset cutoff angle and a 
bond length, the hydrogen bonds present in the majority of a given trajectory can be 
identified to record permanent stabilizing interactions and differentiate them from 
transient interactions [169, 170]. Similarly, using the solvent accessible surface area 
analysis, i.e. by mapping a surface area created using a probe sphere of 1.4 Å and 
accumulating the statistical data, provides a quantitative metric of hydrophobic 
stabilization effects.  
The utility of MD simulations generally depend on the accuracy of the underlying force-
field. Since force-fields are created using empirical energy functions, they are 
parameterized and tuned to specific class of molecules; this introduces a constraint on 
their transferability to model non-native systems or environments and results must often 
be compared to experimental results, not only to verify their accuracy, but also to identify 
where methodological improvements can be made. Thus, there is continued development 
of the basic force-field as well as the simulation methodology. 
Another important consideration is the ability to perform sufficient sampling of the 
combinatorially large number of conformations available to even the simplest of 
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biomolecules [81]. In this respect, a potential disadvantage of molecular dynamics 
calculations is that there is an inherent limitation upon the maximum time step used for 
the simulation (≤ 2 fs). Solvated systems of protein monomers typically consist of 40000 
atoms, and those of higher order complexes such as dimers or membrane-bound proteins 
can be as large as 200,000 to 500,000 atoms. For such system sizes, with current 
hardware and software, simulation times extending into the microsecond regime and 
beyond is an exceedingly difficult and labor intensive endeavor which requires a 
combination of algorithmic enhancements as well as the utilization of high-performance 
computing hardware infrastructure. For example, cutoff distances reduce the number of 
interactions to be computed without loss of accuracy for short-range interactions but not 
for long-range (electrostatic) interactions; to help maintain accuracy, long-range 
corrections such as the particle mesh Ewald algorithm [105, 252] along with periodic 
boundary conditions are typically implemented. Parallelization techniques enable the 
execution of the simulations on supercomputing resources such as 4096 processors of a 
networked Linux cluster.  Although a cluster of this size is a big investment, its 
accessibility is feasible through the US National Science Foundations‟s TeraGrid 
Initiative (founded in 2001) for academic researchers. TeraGrid resources 
(www.teragrid.org) currently include more than a petaflop of computing capability and 
more than 30 petabytes of online and archival data storage, with rapid access and 
retrieval over high-performance networks. Capitalizing on advances in hardware 
architecture, another approach is the creation of custom hardware for MD simulations, 
and offers one-two orders of magnitude enhancement in performance; examples include 
MDGRAPE-3 [230, 232] and ANTON [95, 251].  Recently, graphical processing unit 
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(GPU) accelerated computation has come into the forefront to enable massive speed 
enhancements for easily parallelizable tasks with early data indicating that GPU 
accelerated computing may allow for the power of a supercomputing cluster in a desktop, 
see examples [36, 109]. 
1.3.2 Molecular docking 
Molecular docking can be defined as the prediction of the “correct” bound structure of 
the complex involving a receptor (typically a protein) and a ligand (other proteins, 
nucleic acids or small molecule inhibitors) [181]. The idea behind docking is to generate 
a comprehensive set of conformations of the receptor-ligand complex and then to rank 
them according to their stability. One essential component for the success of a docking 
program is an algorithm for conformational space searching. Ideally, conformational 
searching during docking for both receptor and ligands are necessary. However, to 
enhance computational efficiency, ligand flexibility is considered by most existing 
softwares, while receptors (or proteins) are usually treated as rigid during docking. 
However, the frequently observed changes in receptor structure upon ligand binding 
indicate the importance of receptor flexibility [274] and different versions of receptor 
flexible models with varying degrees of sophistication have been proposed. Among them, 
using MD simulations to pre-generate protein conformers for docking [178] will be used 
in this thesis. Another essential part of a docking program is a fast yet accurate scoring 
function. Many docking programs, for reasons of computational efficiency, usually 
approximate the binding free energy based on the evaluation of a single structure. These 
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scoring functions usually assume that the binding free energy can be estimated by a linear 
combination of pairwise terms [204]: 
       vdW hbond elec conform tor solG G G G G G G  
where, the first four terms are molecular mechanics terms, namely, dispersion/repulsion, 
hydrogen bonding, electrostatics and deviations from the covalent geometry; the fifth 
term models the restriction of internal rotors and global rotation and translation; and the 
last term accounts desolvation upon binding and the hydrophobic effect. This class of 
scoring functions is of practical use for molecular docking and is computationally 
tractable. On the other hand, they certainly have limitations in terms of the accuracy with 
which they represent the free energy of binding due to the various simplifying 
assumptions.  
1.3.3 Free energy perturbation (FEP) 
 
Figure 1.7 Thermodynamic cycle for the calculation of binding affinity change of ligand/substrate due to a 
mutation. 
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In this thesis, we designed a thermodynamic cycle as shown in Figure 1.7 and employed 
the free energy perturbation (FEP) method to calculate the effect of how mutation will 
affect small molecule binding. To calculate the binding free energy change       , we 
can calculate the difference between the free energy changes caused by the particular 
mutation in the bound state (   ) and the unbound state (   ). The binding affinity 
change due to the mutation can be expressed as: 
                              
The free energy changes caused by the particular mutation in the bound state (   ) and 
the unbound state (   ) were calculate by free energy perturbation (FEP) method. In 
general, the free energy difference between two related system A and B, represented by 
the Hamiltonians of    and      can be calculated by  
                
              
where R is Boltzmann's constant, T is the temperature, and     refers to an ensemble 
average over a simulation run for state A.  
In our simulation, systems A and B are defined by the wildtype and mutation states of 
bound or unbound system. In order to improve accuracy, the two thermodynamic states 
are broken into windows, each one involving a small enough interval to allow the 
incremental free energy change to be calculated accurately. A Hamiltonian      is 
defined as 
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Where   can vary from 0 (    ) to 1 (    ). The accumulated free energy change is 
calculated by:  
                 
                
 
    . 
1.3.4 MMPBSA 
While approximate binding free energies are suitable for high-throughput docking, 
stringent rankings or accurate free energies are often needed for lead optimization and 
more detailed examination of binding at the molecular level. Thermodynamic integration 
(TI) and free energy perturbation (FEP) [150, 253] are among the most rigorous free 
energy methods available currently. However, they are too computationally expensive to 
be widely employed. MD-based methods such as Molecular Mechanics Poisson-
Boltzmann Surface Area (MMPBSA) [153] can achieve similar accuracy at a smaller 
computational cost, therefore commonly used for virtual screening of compounds. It has 
produced reasonable binding energies for several systems, and also been employed as a 
post-docking filter in the virtual screening of compounds [136, 188, 254]. In this thesis, 
we use MMPBSA to re-rank the top predicted bound conformation generated by 
molecular docking. 
In a MMPBSA method, the binding affinity between ligand (L) and the protein receptor 
(R) is estimated from the free energies of three species,  
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where all species are assumed to be in water solution. The free energy of each of the 
species is estimated as a sum of four terms:  
                             
where       is the polar solvation energy of the molecule, estimated by the solution of the 
Poisson-Boltzmann (PB) equation,      is the nonpolar solvation energy, estimated form 
the solvent-accessible surface area of the molecule, T is the temperature,      is the 
entropy of the molecule, estimated from a normal-mode analysis of harmonic frequencies 
calculated at the molecular mechanics (MM) level, and     is the MM energy of the 
molecule, i.e., the sum of the internal energy of the molecule (i.e., bonded terms), the 
electrostatics and van der Waals interactions. All the terms in the above equation are 
averages of energies obtained from a number of snapshots taken from MD simulations. 
As the computationally most intensive step of the MMPBSA method is the generation of  
snapshots (geometries) employed in the energy calculations  through MD simulations, in 
order to minimize computing resources, the same geometry is employed for all three 
species (complex, ligand, and receptor), i.e., only the complex is simulated by MD. 
Thereby, the bonded term in MM energy cancels out in the calculation.  
The MMPBSA model, like other implicit models, is derived from the potential of mean 
force based on the assumption that electrostatic and nonpolar contributions to the free 
energy can be treated separately in a additive fashion (this represents a mean-field 
assumption). In the MMPBSA approach, we calculate the salvation terms based on a pre-
defined model for atomic radii and solute dielectric constant, which are simplifying 
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assumptions. The method also makes simplifying assumptions on conformational 
sampling in order to gain efficiency.  
1.3.5 Electronic Structure Methods 
Molecular simulations using the empirical force-field approach are rooted in the validity 
of classical mechanics. Electronic structure methods [71, 89, 96, 99, 196, 207, 209, 228, 
240, 268, 269, 290] that relieve this fundamental assumption are often necessary in force-
field development as well as in understanding chemical reaction pathways and catalytic 
mechanisms. While electronic structure methods are computationally rather demanding, 
recent advances in mixed quantum mechanics molecular mechanics (QM/MM) methods 
also enable us to combine high level electronic structure methods with molecular 
mechanics [22, 44, 46, 68, 72, 76, 78, 87, 88, 106, 127, 128, 146, 157, 178, 190, 191, 
221, 243, 279, 280, 283, 285, 286, 296]. This multiscale description of force-fields 
provides a route to extend the electronic structure methods to the nanometer scale to 
enable the study of biomolecular systems. Compared to their classical counter-parts [268, 
269], the quantum approaches (such as the empirical valence bond [13, 67, 92, 99, 108, 
291]) and mixed QM/MM approaches are more challenging to apply in the biochemical 
context, though several successful demonstrations are available [3, 166]. In this thesis, we 
employed electronic structure methods in force-field development as well as in the study 
of catalytic reaction mechanisms. 
Electronic Structure Methods in Force-field Development: In order to obtain an accurate 
description of molecular parameters (force-field), we require specification of geometric 
parameters such as bond, angle, dihedral angles etc., energetic terms such as partial 
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charges, bond/angle/dihedral stiffness, and contributions of solvation-desolvation. 
Consistent with existing biomolecular force-fields, it is thus essential to parameterize any 
new compound/molecule/chemical modification in the model and extend the force field 
for accurate representation of the model system.This procedure usually involves a series 
of steps [254] described below. The geometry of new compounds is optimized using an 
electronic structure method such as Hartree-Fock (HF) [254] and by using a set of basis 
functions to represent the electronic wave function. Such calculations are facilitated by 
the aid of the quantum chemistry software such as GAUSSIAN (www.gaussian.com 
[91]). The procedure of geometry optimization of the molecule returns the equilibrium 
geometry of the molecule, the spatial electron-density at 0 K, from which the partial 
(Mulliken) charges on each atom are inferred. Moreover, the frequency spectrum of the 
molecule to characterize its vibration spectrum in the ground state is also computed using 
the analysis of normal modes. In order to represent delocalized (low-frequency) motions 
such as torsional oscillations, a torsional energy scan is also performed.  
In determining empirical force field parameters for new compounds, consistency and 
compatibility with the parent force-field is an important criterion. For example, the 
CHARMM27 force-field is commonly used as an all-atom empirical force field for 
biomolecules; it is therefore necessary to develop force-field parameters for new 
compounds consistent with the rest of the CHARMM27 force-field.  
To obtain these parameters [33], partial atomic charges are calculated using CHarges 
from ELectrostatic Potentials using a Grid based method (CHELPG) [178] in 
GAUSSIAN and further adjusted to reproduce interaction energy of H-bond 
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donor/acceptor atoms in the inhibitor compound with water molecules. The 
intramolecular parameters such as molecule geometry and force constants are determined 
by using structural and vibrational data derived from electronic structure calculations. 
Intramolecular force constants are initially assigned based on existing parameters of 
compounds with similar structure and further refined following an automatic procedure 
using a genetic algorithm (GA) to optimize a merit function [263], which matches both 
eigenvalues and eigenvectors estimated using the electronic structure calculations (i.e. 
using GAUSSIAN) to those resulting from a normal mode analysis calculated from 
classical molecular mechanics calculations, i.e. using CHARMM [228, 268]. 
Quantum Mechanics Molecular Mechanics (QM/MM) Simulations: In the QM/MM 
simulations, the system is sub-divided into two sub-regions, the quantum mechanical sub-
region (QM region) where the reactive events take place, and the molecular mechanical 
sub-region (which provides the complete environment around the reactive chemistry) 
[188]. Since electronic structure methods are limited by the number of atoms they can 
handle (typically 50-500), the QM sub-region is restricted to a small number of atoms of 
the total system. For example, in an enzymatic system, the quantum region can consist of 
Mg
2+ 
ions, water molecules within 3 Å of the Mg
2+ 
ions, parts of the substrate molecules 
and the catalytic amino acid residues (such as aspartic acids). The remaining protein and 
solvent molecules are treated classically using the regular classical force-field (such as 
CHARMM27).  
In QM/MM simulations, wave function optimizations are typically performed in the 
quantum (or QM) sub-region of the system using an electronic structure method such as 
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density functional theory (DFT) [180, 228]. In this step, the electrostatic coupling 
between the QM and the MM sub-regions is accounted for: i.e., the charges in the MM 
sub-region are allowed to polarize the electronic wave functions in the QM sub-region. 
The forces in the quantum sub-region are calculated using DFT, on-the-fly, assuming that 
the system moves on the Born-Oppenheimer surface [89]. That is, we assume a clear 
timescale of separation between the electronic and nuclear degrees of freedom and the 
electronic degrees of freedom are in their ground state around the instantaneous 
configurations of the nuclei. The forces on the classical region are calculated using a 
classical force-field. In addition, a mixed Hamiltonian (energy function) accounts for the 
interaction of the classical and the quantum sub-regions. For example, since the QM/MM 
boundary often cuts across covalent bonds one can use a link atom procedure [71] to 
satisfy the valences of broken bonds in the QM sub-region. Also, bonded terms and 
electrostatic terms between the atoms of the QM region and those of the classical region 
are typically included [222].  
From a practitioner‟s stand-point, QM/MM methods are implemented based on existing 
interfaces between the electronic structure and the molecular dynamics programs, one 
implementation is between GAMESS-UK (www.cfs.dl.ac.uk [37]) (an ab-initio 
electronic structure prediction package) and CHARMM [71]. The model system can then 
be subjected to the usual energy minimization and constant temperature equilibration 
runs at the desired temperature using the regular integration procedures in operation for 
pure MM systems; it is customary to carry out QM/MM dynamics runs (typically limited 
to 10-100 ps because of the computationally intensive electronic structure calculations) 
using a standard 1 fs time step of integration. The main advantage of the QM/MM 
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simulations is that one can follow reactive events and dissect reaction mechanisms in the 
active site, while considering the explicit coupling to the extended region. In practice, 
sufficient experience and care is needed in the choices of the QM sub-region and the 
many alternative choices of system sizes, as well as the link-atom schemes need to be 
compared to ensure convergence and accuracy of results [290]. The shorter length of the 
dynamics runs in the QM/MM simulations (ps) relative to the MM MD simulations (ns) 
implies that sufficiently high resolution structures are usually necessary for setting up 
such runs as the simulations only explore a limited conformational space available to the 
system. Another challenge is an accurate and reliable representation of the mixed 
QM/MM interaction terms [238, 295]. These challenges are currently being overcome by 
the suitable design of next generation methods for electronic structure and molecular 
mechanics simulations [52, 193]. 
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Chapter 2 Computational Delineation of Tyrosyl-
Substrate Recognition and Catalytic Landscapes in the 
Epidermal Growth Factor Receptor Tyrosine Kinase 
Domain  
2.1 Introduction 
The recent availability of several crystal structures of the EGFR kinase domain [15, 248, 
284, 289] together with the identification of several kinase-activating mutations [48, 164, 
186] clinically related to enhanced drug response have brought to focus the importance of 
molecular details in the structure-function relationship, including mechanisms for 
substrate recognition and phosphoryl transfer.  
 
Figure 2.1 Structure of EGFR TKD co-crystallized with the bi-substrate analogs.  
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EGFR tyrosine kinase domain (TKD) is a typical tyrosine protein kinase, which catalyzes 
protein phosphorylation reactions by transferring the γ-phosphate group from an ATP 
molecule to the hydroxyl group of tyrosine residues in protein substrates [5]. It shares  
bilobe-fold catalytic domain common to several kinases [5, 30, 110] implying a 
conserved catalytic mechanism [5, 30, 110] in which ATP binds into the cleft between 
the N- and the C- lobes. In addition, two divalent metal (magnesium) ions are thought to 
be involved in the catalytic reaction [5, 110, 145, 256] along with a number of highly 
conserved regions in the catalytic domain, including the glycine-rich loop, the DFG motif 
of the activation loop as well as the catalytic loop serving to position the phosphate of 
ATP and the two Mg
2+ 
ions. Then, by recognizing [225, 255], recruiting and 
phosphorylating a variety of peptide substrates, the kinase regulates several essential 
signaling pathways. Even though a complete elucidation of specificity in tyrosine 
phosphorylation by TKDs continues to be elusive[177], it is believed that the specificity 
of signaling cascades are in-part determined by the sequence identity of phosphor-
tyrosines on substrates [226]. That is, the specificity in-part depends on how the kinase 
recognizes the local sequence of substrate proteins at the P-site (shown in Figure 2.1), 
i.e., the amino acids situated immediately proximal to the P-site [142, 261], denoted by P-
1, P-2, P-3, etc. on the N-terminal side and P+1, P+2, P+3, etc. on the C-terminal side. It 
has been suggested that receptor tyrosine kinases including EGFR TKD show preference 
for substrates with glutamic acid at the P-1 position and large hydrophobic amino acids at 
the P+1 position [118, 123, 149, 245]. The precise relationship of such a sequence 
identity to substrate specificity and the catalytic mechanism is still not understood. 
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Experimental and theoretical studies have demonstrated that, in phosphoryl-transfer by 
kinases and polymerases, nucleophilic attack on the target phosphate proceeds via a 
conformation that resembles a trigonal-bipyramidal transition state [154, 249]. However, 
the phosphoryl-transfer can occur through either an associative or a dissociative 
mechanism (39, 41-44). In the dissociative mechanism, the cleavage of the bond between 
the phosphorus center and the leaving group oxygen precedes the bond formation with 
the attacking nucleophile. On the contrary, in associative mechanism, the bond formation 
between the attacking nucleophile and the phosphorus center precedes the bond cleavage. 
Although it is well accepted that the dissociative mechanism is the preferred mechanism 
for reaction in solution for monoester [64] which are particularly relevant for the reaction 
catalyzed by TKDs, discerning the transition state of protein kinase catalyzed reaction is 
complex, resulting in controversial experimental interpretations [29, 145, 175, 220, 292]. 
Besides, it is also important to understand the catalytic roles of specific residues around 
catalytic site of a protein kinase, in particular, the role of the conserved aspartic residue 
(D813 in EGFR) in the catalytic loop [145, 167, 294]. To address this question in other 
well-characterized kinase systems such as PKA, CDK2, insulin kinase, and MAPK, 
computational methods have been successfully used to investigate the phosphoryl transfer 
reaction [52, 53, 73, 74, 97, 260, 264, 293]. The challenge in extending such studies to 
EGFR kinase is that, while the structure for EGFR crystallized with a bi-substrate (ATP-
peptide analog) is available [289] providing molecular resolution to the ternary complex 
of the kinase/substrate/ATP system, the covalent constraint between the ATP analog and 
the substrate and the fact that the peptide sequence in the bi-substrate ligand is a c-Src 
[159, 288] rather than a native EGFR substrate introduce an important challenge in 
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resolving the structural details of the catalytically productive ternary complex [28]; this 
brings to focus a related but equally important question on how EGFR kinase recognizes 
its native peptide substrates.  
In this chapter, we employ methods of molecular modeling and simulation to (1) 
investigate how the EGFR TKD recognizes the local amino acid sequence of substrates 
proximal to the P-site as, and (2) characterize the EGFR TKD-catalyzed mechanism of 
phosphoryl transfer. Specifically, to address (1) we employ a computational protocol  
combining molecular dynamics simulations, ensemble molecular docking [161, 274], 
and Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) [102, 117, 150, 
153, 231, 253, 266] to investigate the bound conformations of peptide substrates derived 
from two of  autophosphorylation sites of the cytoplasmic tail (C-terminal) region  of 
EGFR TKD [123], namely Y1068 (VPEYINQ) and Y1173 (NAEYLRV). We find that in 
our predicted bound conformations, the substrates bound into the same pocket as the bi-
substrate peptide and that the P-1 glutamic acid residue and the hydrophobic amino acid 
at the P+1 position situate to interact with a highly conserved motif in the protein kinase 
family, namely Val852-Pro853-Ile854-Lys855-Trp856 in EGFR. This motif creates a 
binding surface to form hydrophobic contacts as well as hydrogen bonds to residues close 
to P-site (P0) tyrosine in the substrate and therefore helps to orient the tyrosine residue 
towards the active site. Using our predicted binary complex of EGFR TKD/substrate, we 
modeled the ternary complex structure of EGFR TKD/substrate/ATP and two Mg
2+ 
ions, 
and address (2) by investigating the phosphoryl transfer of EGFR TKD using mixed 
quantum mechanics molecular mechanics (QM/MM) simulations. Our QM/MM 
simulations show that the EGFR protein kinase favors the dissociative mechanism, 
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although an alternative channel through the formation of an associative transition state is 
also possible. Our potential energy scans suggest that the kinase directs the reaction 
through the dissociative channel primarily using a hydrogen bond between the conserved 
aspartic acid residue in the catalytic loop and the hydroxyl group of the substrate. The 
alternative channel can sustain weak activity, but can become significant in non-cognate 
environments where the catalytic aspartic acid is mutated or the enzyme is locked in a 
constitutively inactive conformation. Collectively, our simulations establish key 
molecular rules in operation for the substrate-binding and catalytic landscapes in the 
EGFR TKD. 
 
Figure 2.2 Docking protocol to predict peptide bound conformation to EGFR TKD 
2.2 Methods and Materials 
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We employ a suite of computational methods including molecular dynamics and 
molecular docking (see Figure 2.2), umbrella sampling, and QM/MM simulations to 
investigate molecular mechanisms of substrate recognition (i.e. bound conformation of a 
tyrosyl-peptide) by EGFR TKD and the catalytic mechanism associated with the 
subsequent phosphoryl transfer reaction.  
2.2.1 Molecular dynamics 
All the molecular dynamics simulations in this thesis started with preparing the protein or 
protein complex structure by adding hydrogen atoms and missing residues using the 
CHARMM [37] biomolecular simulation package. The protonation states of histidine 
(HIS) residues were chosen according to recommendations from the WHATIF web 
interface (http://swift.cmbi.kun.nl/WIWWWI). Protonation states for all titratable groups 
distal to  the catalytic site were chosen based on their individual pKa values in aqueous 
solution at a pH 7.0 [200]. The systems were then placed in a water (TIP3 model) box 
with 15Å padding with ions added randomly to neutralize the systems using the Solvate 
and Autoionize Plug-ins in VMD package [121]. The systems were minimized for 50000 
steps with heavy atoms fixed and relaxed for another 50000 steps without any restraints. 
The systems were then gradually heated from 0K to 300K followed by 500ps 
equilibrating runs at constant pressure and temperature to allow the system to reach the 
proper density. A productive trajectory was then generated at 300K and 1atm. The 
simulations were performed using NAMD with CHARMM force field [166] with 
periodic boundaries enforced and long-range electrostatics taken into consideration. 
2.2.2 Molecular docking 
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All the docking simulated in this thesis were performed with AUTODOCK 3.05 [178]. 
Grid maps were constructed as 126126126 points with a grid spacing of 0.184 Å to 
cover the pre-defined binding pocket. The Lamarckian Genetic Algorithm (LGA)[178] 
was applied to explore the conformational space of the substrate. In each docking run, the 
initial population was set to 100 individuals; the maximum number of energy evaluations 
is set to 10
8
; and the generation of GA run is set to 30,000. 
2.2.3 Docking of substrate tyrosyl-peptides Y1068 and Y1173 to EGFR 
TKD 
The active conformation of the wildtype EGFR TKD domain was modeled based on the 
2GS6 structure from the Protein Data Bank [289]. A 10 ns dynamics trajectory was 
generated by molecular dynamics simulation and an ensemble of 100 protein 
conformations was derived by sampling at uniform intervals from the trajectory. Two 7-
residue peptides derived from the c-terminal region of EGFR (corresponding to Y1068: 
namely, VPEYINQ and to Y1173: namely, NAEYLRV) were docked to each snapshot in 
the 100-member ensemble by molecular docking. Five possible bound conformations 
were predicted for each protein conformation, which in total yielded 500 bound 
conformations of tyrosyl-peptide/EGFR TKD for each peptide. 
Since no constraints were imposed in the docking simulation, we employed a screening 
filter to identify those conformations in which the tyrosine-hydroxyl oxygen Y(P0):Oη 
was situated <6 Å from the O2 oxygen of the conserved catalytic aspartic acid residue 
(D813). The choice of 6 Å as the filter-cutoff was made to accommodate direct as well as 
water-mediated hydrogen bonding between the respective groups. The resulting 
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structures were aligned (based on the protein backbone) to the crystal structure of EGFR 
TKD in complex with the bi-substrate ligand, namely 2GS6; conformations in which the 
peptide overlaps with ATP conformation in the bi-substrate structure were further 
discarded. Hence, out of the 500 predicted conformations, only 18 of them satisfied the 
constraints of our filter and were organized into 5 clusters based on RMSD (based on the 
backbone atoms and a cluster cutoff value of 3.0Å). In each cluster, we identified the 
conformation with the lowest binding energy score as the representative for further 
analysis.   
In order to further sort the binding conformations generated by the ensemble docking 
protocol, we employed MMPBSA [102, 117, 150, 153, 231, 253, 266] to calculate the 
binding free energy. For each of the predicted bound conformations, a 1 ns trajectory was 
generated using molecular dynamics. The MMPBSA energy of each modeled complex 
was calculated as the average of the single point MMPBSA scores of 500 snapshots 
derived from the 1 ns simulation; the waters molecules and mobile ions were removed 
before the MMPBSA score calculation. In the MMPBSA calculation, the molecular 
mechanics energy, UMM, was evaluated using an infinite cutoff for non-bonded 
interactions. The electrostatic contribution to the solvation free energy, WPB, was 
calcuated with Poisson-Boltzmann Solver in CHARMM [126]. The reference system was 
assigned a solvent dielectric of 1 and 0 M salt concentration and the solvated system was 
assigned a dielectric of 80.0 and 100 mM salt concentration. The nonpolar contribution to 
the solvation free energy, WSA, was approximated with the suface area model 
WSA=[0.00542 kcal/mol/Å
2
]SASA +0.92 kcal/mol [215], where the molecular surface 
area (SA) was estimated with a 1.4 Å slovent probe radius. The translational and rotional 
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entropy loss upon binding was estimated based on the change of freedom of center of 
mass as well as orientations (Eular Angles) by following the procedure described by 
Swanson et.al. [253] . Other (vibrational) entropy changes were neglected in this thesis.  
The top-ranked conformation of peptide Y1068 with EGFR TKD identified based on the 
MMPBSA score was chosen as the initial bound structure for further analysis of the 
catalytic mechanism. The ATP was placed in homology with the bi-substrate structure 
(PDB ID: 2GS6) [289] and two Mg
2+
 ions were placed in homology with those resolved 
in the crystal structure of PKA (PDBID:1ATP) [52]. A 10 ns molecular dynamics 
simulation was performed on the ternary complex of ATP/substrate-Y/EGFR TKD.  
2.2.4 Sampling the Pre-Catalytic Free Energy Landscape 
Since the positions and orientations of the ions and ATP relative to the substrate tyrosines 
in our initial modeled structures were determined either from a bisubstrate ligand 
complex or by homology with protein kinase A (see above), prior to QM/MM 
simulations, we explored the classical free energy landscape along an a priori-chosen 
reaction coordinate 1 (the tyrosyl O-ATP P nucleophilic attack distance). For 
computing the free energy landscape, the probability distribution P( 1) is calculated by 
dividing  1 into several (6-7) windows. The histograms for each window were collected 
by harvesting classical molecular dynamics trajectories of length 200 ps per window 
using a harmonic restraint 0.5×K×(  1- 1
i,0
)
2,  1
i,0
 being the pre-set of the reaction 
coordinate characterizing the i
th
 sampling window, and K=20 kcal/mol/Å
2
 being the force 
constant for the restraint along  1. The sampling data from the different windows were 
then processed using the weighted histogram analysis method (WHAM) [213]. 
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2.2.5 Quantum Mechanics Molecular Mechanics (QMMM) Simulations 
The QMMM approach we adopted was based on an existing interface between 
GAMESS-UK [222] and CHARMM [37]. For the quantum region, we chose the two 
Mg
2+ 
ions, water molecules within 5 Å of the Mg
2+ 
ions, segments of the ATP, the 
tyrosine residue of the substrate, and two catalytic residues (D813 and D831), yielding a 
total of 60 atoms . In order to reliably handle the phosphorous chemistry, the quantum 
region was treated using density functional theory with a B3LYP exchange correlation 
functional and a 6-31G* basis set [254], and the remaining protein and solvent molecules 
were treated classically using the CHARMM27 force field. Since the QMMM boundary 
cuts across covalent bonds, we applied the single link atom procedure [89] to satisfy the 
valences of broken bonds in the QM region. The electrostatic interactions between the 
quantum region and the classical atoms belonging to groups at the QMMM boundary 
were discarded as this choice has been shown to enhance the accuracy in the resulting 
energies and geometries [71]. We have extensively explored this choice of the QMMM 
region (including sensitivity to the size of the QM region, and the functional/basis set 
combination) in our prior studies of closely related systems [203, 201, 202]; others have 
validated the choice of the link atom [71]. Non-bonded van der Waals (VDW) 
interactions were treated by applying a switching function at 10 Å and truncating the 
VDW potential energy smoothly at a cutoff distance of 12 Å. The forces in the quantum 
region were calculated on-the-fly, assuming that the system moves on the Born-
Oppenheimer surface defined by the QMMM Hamiltonian. The system was first 
subjected to 1200 steps of the adopted basis Newton-Raphson (ABNR) minimization and 
subsequently QMMM MD simulations were performed during which the systems were 
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first heated to 300 K and then subjected to constant temperature of 300 K dynamics using 
a Langevin thermostat for 10 ps and a standard 1 fs time step of integration.   
2.2.6 Catalytic Reaction Pathways 
The exact reaction coordinate is complex and multi (high) dimensional and a quantitative 
estimate of the free energy landscape can only be obtained using efficient long-time 
sampling approaches [26, 38, 56, 79, 208], which remain prohibitively expensive for 
QMMM applications due to large computational cost. Although we believe that the true 
reaction coordinate is complex, in the spirit of the a recent study [212], we described the 
reaction pathways in terms of several simple reaction coordinates, . For mechanisms of 
phosphoryl transfer through associative mechanism,  includes the reactive distance 
tyrosine O- ATP P, tyrosine O- ATP O2/3, and ATP P- ATP O2/3 distances. For 
mechanisms of phosphoryl transfer through dissociative mechanism, in addition to the 
three distances,  includes the coordinate for proton abstraction, namely tyrosine OH- 
D830:O2. In order to drive the system along a reaction coordinate, we performed 
restrained minimization as well as restrained sampling simulations using the QMMM 
Hamiltonian along  by augmenting the Hamiltonian with a potential bias term 
(1/2)K(||-0)
2
; here K is the effective spring constant (ranging between 10 and 30 
kcal/mol/Å
2
) and 0 are reference values for sampling in different windows of . 
Complete pathways were assembled by varying the offset distances 0 in increments of 
0.05 Ǻ, where the positive and negative increments represent the directionality of the 
energy scan. The reaction paths were computed by energy-minimizations in the presence 
of restraints and recalculating the single-point energies in the absence of the constraints. 
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For our choice of the increments of 0, calculations performed in forward and reverse 
directions satisfied path reversibility in configurations as well as energy values. 
Following the energy scans, constant temperature restrained dynamics runs of 300 fs-1ps 
for each choice of 0 was also performed to ensure that the reaction path was robust to 
thermal fluctuations.  
2.3 Results 
2.3.1 Tyrosyl-Peptide Substrate Recognition by EGFR TKD 
Following the computational protocols described above, 500 bound conformations were 
predicted using ensemble docking protocol for binding of EGFR TKD to a seven-residue 
native EGFR peptide with P0 corresponding to autophosphorylation site Y1068 
(VPEYINQ). Since a large number of the resulting structures showed peptide 
conformations in which the tyrosine residue was far from the active site, we constructed a 
histogram of D: the distance between the tyrosyl-oxygen and the O2 oxygen of the 
conserved catalytic aspartic acid residue (D813), see Figure 2.3A, and only considered 
those conformations with D < 6 Å; this choice for the cut-off is intended to cover 
situations where the hydroxyl group of the peptide forms a hydrogen bond with O2 of 
D813, either directly, or through  a water mediated interaction. In addition, conformations 
in which the peptide substrate overlaps with the position of ATP (quantified using the bi-
substrate conformation in the PDBID:2GS6 structure) were further discarded. Thus, 
among the 500 predicted conformations, 18 structures of the TKD-substrate complex 
satisfied our constraints, which were categorized into 5 clusters based on root-mean-
squared deviations (RMSD) of the backbone heavy atoms. 
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Table 2.1 Rescoring of the top five predicted peptide conformations predicted by ensemble docking 
(showed in Figure 2.3B) using MMPBSA based on 1-ns MD simulation. The RMSD (Å) is calculated 
between the backbone atoms of the central five residue of the modeled peptide to the backbone atoms of 
the five residue peptide portion of the bi-substrate in structure 2GS6.The unit of energy is Kcal/mol.  
Conf.                   
         
             
       
           
         RMSD 
1 -157.4 153.3 -7.7 5.2 4.2 -2.4 5.45 
2 -131.4 121.9 -7.5 5.5 4.3 -7.2 5.09 
3 -134.4 109.4 -6.5 4.9 4.3 -22.2 2.72 
4 -206.3 197.4 -7.9 5.4 4.2 -7.3 5.97 
5 -107.5 103.7 -7.3 5.2 4.3 -1.6 3.92 
 
The five conformations with the lowest score in each cluster are depicted in Figure 2.3B, 
along with the bi-substrate conformation from the PDBID:2GS6 structure. The computed 
MMPBSA binding free energies Gs of the five conformations are provided in Table 2.1; 
as expected, the binding free energy is dominated by the difference between the 
unfavorable polar solvation and the favorable molecular mechanics terms. Interestingly, 
the conformation 3, which corresponds to the lowest MMPBSA score, also aligns most 
closely to the bi-substrate conformation as shown in Figure 2.3B and Table 2.1.  
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Figure 2.3 Results of docking peptide Y1068 to EGFR TKD. A) Histogram of the distance between the 
oxygen in hydroxyl group of the tyrosine and the oxygen atom in the carboxylate group of the D813 of all 
the 500 predicted conformations by ensemble docking. Conformations with this distance less than 6 Å were 
clustered into 5 clusters based on their backbone RMSD. B) Five predicted peptide clusters of Y1068 
bound conformation generated by ensemble docking which satisfied the distance criteria in A. The bi-
substrate peptide binding pocked are shown as the back surface area for comparison. All the five 
conformations were re-ranked using MMPBSA, shown in Table 2.1. C) The bound conformation of peptide 
Y1068 to EGFRTK in the presence of ATP and two MG2+ ions after 10 ns MD equilibrium. ATP are 
depicted in red, MG2+ in green, peptide in blue and residues in EGFR TKD which are interacted with the 
peptide in yellow. D) A close look of main interactions between the peptide and kinase: Y(P0) hydrogen-
bonded with D813; E(P-1) formed a salt bridge interaction with residue K855; hydrophobic residue I(P+1) 
interacted with a hydrophobic surface in EGFR TKD consisted of residue V852-P853-I854-W856. All the 
hydrophobic residues are depicted as transparent surface to show the interaction.  
A 9-ns MD simulation performed using conformation 3 in the presence of ATP and two 
Mg2+ ions reached steady state after 3 ns (Figure 2.4). The peptide backbone is stable 
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during the entire simulation as monitored by the backbone RMSD relative to the initial 
conformation (Figure 2.4). Therefore our predicted substrate conformation emerges to be 
in close alignment with the bi-substrate structure in PDBID:2GS6 structure as shown in 
Figure 2.3B. The side-chain residues, however, adjust conformations to result in stable 
hydrogen bonds and hydrophobic interactions in the final predicted bound structure of the 
ternary complex (EGFR TKD/tyrosyl-substrate/ATP) as shown in Figure 2.3C&D.  
 
Figure 2.4 Evolution of RMSD and key distances for 10 ns MD simulation. The color schemes are: the 
RMSD calculated based the backbone atoms of the central 5 residue of the peptide conformation to the 
initial conformation (red); the distance between D813:O2 and Y(P0):Oη (green); the distance between 
Y(P0):Oη  and ATP:P (purple); and the salt bridge distance between K855 and E(p-1) (light blue).  
The predicted conformation (Figure 2.3C&D) provides new insights into the substrate 
recognition mechanism of EGFR TKD: (1) with respect to the P0-tyrosine, the C-
terminal region of the peptide is anchored into a binding pocket formed by residues in the 
C-terminal region of EGFR activation loop, and the N-terminal of the peptide extends to 
the front of the C-terminal lobe of EGFR TKD (Figure 2.3C); (2) The hydroxyl oxygen 
of the P0 tyrosine is 2.9 Å away from the O2 oxygen atom of residue D813, within a 
hydrogen bond distance (Figure 2.3D); (3) the P-1 glutamic acid residue forms a salt-
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bridge with a highly conserved lysine residue (K855); and (4) the isoleucine in P+1 
position situates in a hydrophobic pocket formed by Val852, Pro853, Ile854 and Trp856 ( 
Figure 2.3D). 
 
Figure 2.5 Results of docking peptide Y1173 to EGFR TKD. A) Six predicted peptide clusters of Y1173 
bound conformation generated by ensemble docking which satisfied the distance criteria in Figure 2.3A. 
The bi-substrate peptide binding pocked are shown as the back surface area for comparison. All the 6 
conformations were re-ranked using MMPBSA, shown in Table 2.2. B) A close look of main interactions 
between the peptide and kinase: Y(P0) hydrogen-bonded with D813; E(P-1) formed a salt bridge 
interaction with residue K855; hydrophobic residue L(P+1) interacted with a hydrophobic surface in EGFR 
TKD consisted of residue V852-P853-I854-W856. All the hydrophobic residues are depicted as transparent 
surface to show the interaction. 
To further validate the robustness of this predicted mode of tyrosyl-substrate interaction, 
we also predicted the bound conformation of a different EGFR-native peptide sequence 
(NAEYLRV) derived from the auto-phosphorylation site Y1173 of EGFR (shown in 
Figure 2.5 and Table 2.2). The conformation predicted for Y1173 is very similar to that 
for Y1068 (Figure 2.5B). In particular, the hydrogen bond between the hydroxyl of 
tyrosine and D813, the salt-bridge between E(P-1) and K855, and the hydrophobic 
contact between L(P+1) and VAL852-Pro853-Ile854 are all preserved.  
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Table 2.2 Rescoring of the top six predicted peptide conformations predicted by ensemble docking ( Figure 
2.5) using MMPBSA based on 1-ns MD simulation. The RMSD (Å) is calculated between the backbone 
atoms of the central five residues of the modeled peptide to the backbone atoms of the five residues in the 
peptide portion of the bi-substrate in structure 2GS6. The unit of energy terms is Kcal/mol. 
Conf.                  
         
             
       
           
         RMSD 
1 -436.5 394.6 -8.0 5.9 4.5 -39.4 9.6 
2 -238.0 217.1 -6.9 4.7 4.3 -18.8 10.0 
3 -243.8 226.2 -8.1 5.4 4.3 -16.1 7.9 
4 -114.2 111.8 -7.4 5.1 3.9 -0.7 10.6 
5 -297.0 241.3 -7.1 5.3 4.7 -52.8 3.6 
6 -250.1 228.5 -8.0 5.4 4.3 -19.9 9.7 
2.3.2 Pre-Catalytic Conformational Landscape Orchestrates Multiple 
Reaction Channels 
 
Figure 2.6 Pre-Catalytic Conformational Landscape along the the nucleophilic attack distance a.   
During the course of the MD simulation of the ternary complex, the conformational 
equilibration of ATP and the two Mg
2+
 ions relative to the substrate tyrosine resulted in 
small rearrangements of the phosphate tail of ATP within the active site. Hence, we chose 
to explore the free energy landscape for the pre-organization of the nucleophilic attack 
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distance a (Y(P0):Oη - ATP:P distance) as this distance is most relevant to catalysis and 
most sensitive to the phosphate tail conformation (Figure 2.6). In conformation 1, 
obtained from energy minimization of our model structure, a  4 Ǻ. However, in the 
course of umbrella sampling, the system settles into another metastable state with a <3 Ǻ 
(conformation 2), surpassing a nominal free energy barrier of 3.5 kBT (2 Kcal/mol). This 
subtle pre-catalytic conformational transition corresponds to a conformational 
rearrangement of -phosphate of ATP (compare snapshots). An analysis of conformations 
within the window corresponding to conformation 2 revealed that the proton of the 
tyrosine-hydroxyl (Hη) is primed for transfer to two possible positions owing to two 
mutually exclusive hydrogen bonds: (1) hydrogen bonded to O2 oxygen of D813 
(indicated by a small value of I), and (2) hydrogen bonded to the O1 oxygen of ATP 
(indicated by a small value of II).  
 
Figure 2.7 Normalized histograms representing the distributions of values for the distances between the 
proton of the substrate tyrosine hydroxyl and (A) the O2 oxygen of D813 in EGFR or equivalent in ErbB3 
(I) or (B) the O1 oxygen of ATP (II) recorded in our simulations of the ground state (reactant) 
dynamics.  
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We hypothesize that the bimodal distributions of I and II values represented in the 
normalized histograms in Figure 2.7 serve to select either of two competing catalytic 
routes, labeled as pathways I and II in Figure 2.8 for proton transfer and concomitant 
phosphoryl transfer. We explore this hypothesis further by investigating the possible 
mechanisms of phosphoryl transfer in EGFR TKD following the protocols for QM/MM 
minimization and QM/MM MD simulations. Our simulations (see Figure 2.9) reveal that 
the phosphoryl transfer via pathway I in which the proton is abstracted through the 
catalytic aspartic acid residue can occur via both the dissociative and associative 
mechanisms, while pathway II supports only the associative mechanism. For pathway I, 
(highlighted red in Figure 2.8), the phosphoryl transfer step occurs through either a 
dissociative mechanism (Figure 2.9A), or an associative mechanism (see Figure 2.9B), 
and proceeds concomitant with migration of the proton from the hydroxyl group of the 
tyrosine substrate to the O2 oxygen of D813. In the dissociative reaction channel, the 
sum of the nucleophilic attack distance a (between Y-OH and ATP P) and the bond-
cleavage distance c (between ATP P and ATP O2/3) in the transition state is greater 
than the corresponding sum in the reactant and product states; this scenario is reflected in 
Figure 2.9A where the a+c values for transition state (TS) are greater than those for 
Rectant (R) or Product (P) states, i.e., the TS region lies above the line joining the R and 
P states in the a versus c plot.  In contrast, a nucleophilic attack through an associative 
mechanism is evident in Figure 2.9B where the a+c values for TS are smaller than 
those for R or P, i.e., TS lies below the line joining the R and P in the a versus c plot. 
Pathway II (highlighted blue in Figure 2.8) is characterized by the migration of the proton 
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from the hydroxyl group of the tyrosine substrate to the O1 oxygen of ATP and the 
subsequent transfer of the proton to the O3 atom of ATP.  The phosphoryl transfer takes 
place concomitant with the proton transfer steps but only through an associative 
mechanism, see Figure 2.9C; interestingly, for this channel, our attempts to drive the 
system through a dissociative mechanism yielded an associative mechanism with the O2 
atom of ATP playing the surrogate (as the leaving group) to the O3 atom of ATP.  
 
Figure 2.8 Proposed schematic of pathway for phosphoryl-transfer in EGFR-TKD. Mg2+ ions and the 
catalytic aspartates (D831) are marked. Two potential pathways for proton migration (concomitant with 
phosphoryl-transfer) are shown. Pathway I (red) involves proton abstraction from the substrate tyrosine –
OH group by D813 of EGFR, and pathway II (green) involves proton migration to the O1 oxygen of ATP. 
I and II denote distances between the proton of the substrate tyrosine hydroxyl and either the O2 
oxygen of D813 (I) or the O1 oxygen of ATP (II). The nucleophilic attack distance, a (distance 
between the tyrosine oxygen and the ATP P) and the bond cleavage distance, c (distance between the 
ATP P and ATP O2/3) are also noted. 
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Figure 2.9 QM/MM results for proposed pathways. (A)&(D): Pathway I and dissociative; (B)&(E): 
Pathway I and associative; and (C)&(F): Pathway II and associative. R = reactant; P = product; and TS = 
transition state characterized by a trigonal bipyramidal geometry about P. (A-C) Distributions of values for 
the nucleophilic attack distance, a (distance between the tyrosine oxygen and the ATP P) and the bond 
cleavage distance, c (distance between the ATP P and ATP O2/3) along the reaction pathways. (D-F)  
Energy changes along the reaction pathways in QM/MM simulations for the noted mechanisms.  
In Figure 2.9(D-F), we depict the computed energy changes along the reaction pathways 
in active EGFR TKD, which suggest that for EGFR, the dissociative mechanism of 
phosphoryl transfer through pathway I corresponds to the lowest activation energy, Ea=16 
kcal/mol (Figure 2.9D), while energy profiles for the associative mechanisms through 
pathways I and II yield barriers of 24 kcal/mol (Figure 2.9E) and 26 kcal/mol (Figure 
2.9F), respectively.  
2.4 Discussion 
Crystal structures of multiple TKDs have already been solved, which has led to important 
insights in understanding the kinase function. However, most of these crystal structures 
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are solved in the presence of ATP analogs and small molecule inhibitors. Due to the 
relatively low binding affinity of the interaction between TKD and peptide substrates, 
crystallization of TKD-peptide substrate complexes is still a challenge using experimental 
techniques. In this chapter, we suggest that a rich landscape exists for the binding of 
tyrosyl-substrate and subsequent pre-catalytic and catalytic events in the ternary complex 
of EGFR TKD/ATP/tyrosyl-substrate, from which we outline new molecular rules, which 
may, in-part, contribute to specificity in phosphorylation reactions.  
Our ensemble molecular docking protocol is successful in predicting bound 
conformations of a 7-residue peptide sequence derived from the C-terminal tail region of 
EGFR to EGFR TKD, with predicted bound conformation very similar to that found in a 
crystal structure of a bi-substrate analog co-crystalized with EGFR TKD [289] (PDBID: 
2GS6). In our predicted complex, the aspartic residue D813 forms a hydrogen bond with 
the hydroxyl oxygen the P0 tyrosine of the peptide substrate. The aspartic residue has 
been shown to hydrogen-bond with the hydroxyl group of serine/threonine/tyrosine in 
other kinase systems [119, 235, 292]. In the only existing EGFR TKD/bi-substrate analog 
structure (i.e. PDBID: 2GS6), the distance between the aniline nitrogen and the O1/2 
oxygen of D813 is 6.37 Å, which makes it difficult to ascribe a role for the aspartic 
residue. The conformation in our modeled ternary complex clearly places the hydroxyl 
oxygen of the P0 tyrosine 2.9 Å away from the O2 oxygen atom D813, i.e., within 
hydrogen bonding distance, which is consistent with the conceived role of D813 as a 
facilitator of proton abstraction. 
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Moreover, it has been suggested that protein tyrosine kinase (including EGFR) select 
substrates with glutamic acid at the P-1 position and large hydrophobic amino acids at the 
P+1 position [85, 86, 118, 123, 149, 245]. Our predicted peptide bound ternary complex 
suggests that a highly conserved region, corresponding to Val852-Pro853-Ile854-Lys855-
Trp856 in EGFR TKD is essential for substrate binding: Lys855 forms a salt bridge with 
the highly preferred glutamic acid residue at the P-1 site, and the hydrophobic pocket 
formed by Val852, Pro853, Ile854 and Trp856 serves to anchor a large hydrophobic 
residue at P+1 position. This observed binding mode for our top-ranked configuration is 
consistent with the hypothesis that the substrate binding surface formed through 
hydrophobic contacts and hydrogen bonds  help orient the tyrosine residue for catalysis 
[149]. Collectively, this extended region, i.e. Val852-Pro853-Ile854-Lys855-Trp856 in 
EGFR, has been identified as a highly conserved motif in the protein tyrosine kinase 
family [28], which further adds significance to our predicted conformation for the ternary 
complex.  This allows us to conclude that a conserved binding surface on the kinase 
sandwiching the P0-tyrosine and making hydrophobic contact to the  P+1 and hydrogen 
bond with P-1  residues, respectively, helps orient the tyrosine residue for catalysis [149]. 
Interestingly, the corresponding motif in serine/theronine kinase, with a sequence of 
Gly200-Thr201-Pro202-Glu203-Tyr204 in PKA, has been named as P+1 binding pocket 
and shown to be critical for substrate specificity [35, 104, 149]. In this case, the glutamic 
acid residue (E203) in this motif has been proposed  to interact with preferred positively 
charged residues of the N-terminal site in PKA substrates [149], and residues Gly200, 
Pro 202, Thr201 and Tyr204 favor a hydrophobic residue in the P+1 position [261].   
49 
 
Two of the main points of contention in kinase-catalyzed phosphoryl transfer reactions 
are whether the phosphoryl-transfer reaction occurs through an associative or a 
dissociative mechanism (39, 41-44) and whether the conserved aspartic (D813 in EGFR) 
functions as an acceptor for proton transfer from the hydroxyl group of the substrate. 
With the predicted peptide bound conformation, we were able to build the ternary 
structure of EGFR TKD and peptide with ATP and Mg
2+
 ions, and investigate the 
mechanistic details of EGFR TKD catalytic reaction mechanism using QM/MM 
simulations. Based on a pre-catalytic energy landscape of -phosphate of ATP we 
identify two alternative preferred proton positions of the tyrosine hydroxyl based on 
which we hypothesize two possible pathways: Pathway I involves proton abstraction 
from the substrate tyrosine hydroxyl group by D813 of EGFR, and pathway II involves 
proton migration to the O1 oxygen of ATP. Indeed, our QM/MM simulations support 
both pathways, with the phosphoryl transfer via pathway I sustained via both dissociative 
and associative mechanisms, while that via pathway II sustained by just the associative 
mechanism. The dissociative mechanism through pathway I has the most favorable 
energy barrier of 16 kcal/mol, while energy profiles for the associative mechanisms 
through pathways I and II each yield barriers of 24 kcal/mol. Combined with the pre-
catalytic reaction energy barrier, our estimate for the net energy barrier Ebarrier for 
activation through the most favorable reaction channel (i.e. for pathway I through 
dissociative mechanism) in the active EGFR TKD is 16+2=18 kcal/mol. This value 
compares favorably with the experimental value for the free energy barrier for EGF 
activated receptor system in the cellular context for which 
Gbarrier=kBTln[kBT/(kcath)]=18.5 kcal/mol was estimated from the reported kcat of 17.4 
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min
-1 
by Gibbes-Johnson et. al. [84]. Our estimate for the net energy barrier Ebarrier for 
activation through pathway II for active EGFR TKD is 24+2=26 kcal/mol. This translates 
to a kcat of 10
-6
 s
-1
 or a reduction by at least a factor 10
-6
 relative to the experimental kcat 
of EGF activated receptor or a factor of 10
-5 
relative to experimental kcat in the absence of 
EGF [85, 185]. The reduction in kcat manifests itself as little or very weak residual 
activity through pathway II, which is consistent with recent experiments [147, 244]. 
Given that the protonation states of titratable side-chains in the active site can have 
considerable effect on the stability of the ground state as well as on the energies of the 
reaction landscape, we explored the different protonation states of the conserved catalytic 
residue D813 in EGFR. Multiple protonation states of the conserved catalytic residue 
(D831 of the DFG motif) was not considered because the location is relatively remote 
from the atoms involved in the catalytic reaction pathway. Although recent studies of the 
Abl kinase have reported that the protonation state of this residue is important in the 
flipping of the DFG motif toward the active conformation [257]. Such a flip for EGFR is 
already facilitated, even in the unprotonated state for D831, by kinase dimerization [162]. 
For the D813-protonated system, the phosphoryl transfer step occurs through an 
associative mechanism and proceeds with the simultaneous migration of the proton from 
the hydroxyl group of the tyrosine substrate to the O1 oxygen of D813 and the migration 
of H2 of the protonated O2 oxygen of D813 to O3 atom of ATP (data not shown). Our 
attempts to drive the system through a dissociative mechanism yielded an associative 
mechanism with the O2 atom of ATP playing the surrogate (as the leaving group) to the 
O3 atom of ATP.   
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Figure 2.10 Possible catalytic reaction pathway for ErbB3 modeled by QM/MM simulation. 
ErbB3/HER3 is another member of the human epidermal growth factor receptor 
(EGFR/HER) or ErbB receptor tyrosine kinase family. ErbB3 is considered to be an 
inactive pseudokinase because it lacks several key conserved (and catalytically 
important) kinase domain residues – including the catalytic base aspartate. Very recently, 
our collaborator, Dr. Mark Lemmon‟s laboratory, reported that despite this residue 
alteration, the kinase domain of ErbB3 retains phosphoryl-transferase activity, as 
evidenced by trans-autophosphorylation of the purified ErbB3 intracellular region [237]. 
Kinase activity appears to be ~1000-fold weaker than that seen for EGFR. Moreover, 
they showed that the ErbB3 kinase domain binds ATP with a KD of approximately 
1.1 M, similar to that seen for known active kinases. A crystal structure showed that the 
overall structure of ErbB3-TKD
665-1001
 closely resembles the inactive conformations of 
the EGFR, ErbB4, and Src kinases [198, 287]. The structure also clearly showed the 
electron density for both AMP-PNP and Mg
2+
, which are similarly positioned as in the 
EGFR TKD structures.  
52 
 
To address this observation, we hypothesized that the weak kinase activity of ErbB3 
might utilize a mechanism distinct from that seen in other kinases, and might be carried 
out by the „inactive-like‟ state. We therefore undertook quantum mechanics molecular 
mechanics (QM/MM) simulations to delineate the energy landscape of phosphoryl-
transfer from ATP to a substrate tyrosine catalyzed by the ErbB3 structure, and compared 
the outcomes with those seen in parallel computational studies of EGFR. Due to the 
presence of an asparagine (rather than aspartate) at N815, pathway I proposed for EGFR 
is not sustainable in ErbB3. However, like active EGFR TKD, the proton migrates to the 
O1 oxygen of ATP, through pathway II in Figure 2.10. Phosphoryl-transfer concomitant 
with this pathway can be catalyzed by ErbB3 in the inactive-like conformation, although 
it is predicted to be several orders of magnitude slower (estimated Ea is 24 kcal/mol) than 
the most favorable reaction channel in EGFR (i.e. for pathway I through a dissociative 
mechanism) – consistent with experimental observations. 
Indeed, a D813A-mutated variant of EGFR variant has been reported to retain its ability 
to promote EGF-dependent DNA synthesis and MAP kinase activation despite exhibiting 
greatly reduced receptor autophosphorylation [65]. A low level of autophosphorylation in 
D813A-mutated EGFR, similar to that shown for ErbB3, may therefore be sufficient to 
mediate certain key aspects of its signaling. 
ErbB3 signaling is important in development of resistance of NSCLC to the EGFR 
inhibitor gefitinib through amplification of the gene for Met [80], the hepatocyte growth 
factor receptor. ErbB3 also plays a key role in the ability of ErbB2-overexpressing cells 
to escape growth inhibition by the EGFR/ErbB2 dual-specific kinase inhibitor lapatinib 
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[229]. Our data suggest that evaluating the signaling importance of ErbB3‟s weak kinase 
activity is also worthwhile, and could represent a valuable therapeutic target. Indeed, 
ErbB3 autophosphorylation in vitro is not inhibited by lapatinib or by the EGFR 
inhibitors gefitinib or erlotinib, leaving open the possibility that ErbB3 kinase activity 
promotes resistance to growth inhibition by EGFR/ErbB2-targeted drugs. If this is the 
case, selective inhibition of the ErbB3 kinase could be an additional effective therapeutic 
strategy. 
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Chapter 3 Interaction of Erlotinib to Different 
Conformational States of the Epidermal Growth Factor 
Receptor Tyrosine Kinase Domain (EGFR TKD) 
3.1 Introduction 
EGFR and other ErbB-family receptor tyrosine kinases have been associated with the 
development, progression and aggressiveness of a number of malignancies [173, 233]. 
The EGFR kinase has long been recognized as a potential drug target.  Small molecule 
receptor tyrosine kinase inhibitors (TKI) for EGFR TKD are of significant interest as 
cancer therapeutic drugs [61]. Erlotinib and gefitinib are two EGFR TKD inhibitors 
which have been approved for the treatment of advanced Non-small cell lung cancer 
(NSCLC) [8, 242]. These two drugs caused a dramatic response in a sub-group of 
patients in clinical trials. A class of mutations, including the point mutation in the 
activation loop (L834R), have been reported correlate highly with favorable clinical 
responses of patients to gefitinib and erlotinib [48, 164, 186]. The discovery of these 
mutations and their correlation with the drug response has fueled an intense interest in 
studies of the oncogenic effects and drug binding properties of these mutations. Although 
a lot effort has been made, a mechanistic basis for such a correlation remains unclear.  
While many factors may contribute to drug response [80, 101, 244], a basic question to 
be answered is whether the mutations will directly affect the drug binding. Available 
crystal structures have shown that L834R EGFR TKD shares a very similar fold with the 
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wildtype kinase and gefitinib was shown to be bound very similarly to wildtype and 
L834R mutatant EGFR TKD [77, 284]. Erlotinib complexed with wildtype EGFR TKD 
[248, 284] shows a very similar binding mode to that of the gefinitb EGFR TKD. Despite 
the similarity in binding modes, several groups have reported varying results for the 
binding affinities of gefitinib and erlotinib to EGFR TKD (shown in Table 3.1), thereby 
creating some controversy over the notion that the binding mechanism is a common one. 
Although two separate studies [83, 101] reported no overall effect of the mutations on 
drug binding, other studies have claimed an increase in binding affinity for the drug in the 
L834R mutant (relative to wildtype) [48, 284].  
Table 3.1 Binding affinities reported for  Erlotinib and Gefitinib binding to EGFR TKD. 
EGFR 
 
Ki (nM) 
Erlotinib Gefitinib 
WT 0.67[83] 17.5[48] 0.9[83] 0.19[101] 53.5[284]  
L834R 0.97[83] 6.26[48] 1.3[83] 0.20[101] 2.6[284] 
 
Like many other kinases, two EGFR TKD conformations, namely active and inactive, 
have been captured in crystal structures [248, 276, 284, 288]. Both erlotinib and gefitinib 
were solved in complex with active EGFR TKD [248, 284], while another inhibitor, 
lapatinib, was crystallized in an inactive EGFR TKD conformation. Such structural 
studies have lead to a prevailing conclusion that erlotinib/gefitinib are specific to active 
EGFR TKD form whereas lapatinib preferentially binds to the inactive conformation. 
L834R kinase structure has been found to adopt a similar conformation to the active 
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wildtype structure. As the L834 residue lies in the helical turn of the activation loop in 
the inactive state of the kinase, it has been proposed that mutation L834R will destabilize 
the inactive structure by disrupting the hydrophobic interaction which stabilizes the 
relatively displaced αC-helix in the inactive state, thereby providing an activating 
stimulus. As a result of the assumed preference of active form of EGFR TKD in L834R 
system, it has been proposed that a tighter binding of erlotinib and gefitinib would result 
in the mutant TKD. Moreover, very recently, a new experimental study has shown that 
the relative selectivity of erlotinib to the active-state EGFR TKD is only 5-10 fold higher 
than that to inactive-state EGFR TKD[199], which raises the possibility of crossover 
binding of these inhibitors to  inactive TKD conformations. To test the hypothesis that 
L834R affects inhibitor binding by altering the equilibrium between active and inactive 
states of EGFR TKD, a detailed study of the binding mechanism of erlotinib/gefitinib to 
wildtype and L834R TKD is necessary.  
In this chapter , we computationally docked the erlotinib to L834R mutated EGFR TKD 
using an induced fit docking protocol, and then compared the binding  of erlotinib with 
wildtype and L834R mutated TKD using molecular dynamics. We also employed free 
energy perturbation to further elucidate the free energy difference between wildtype and 
L834R systems. Our results suggested that erlotinib binds in a similar fashion to wildtype 
and mutated kinase systems in the active form. We further compared the erlotinib binding 
with both active and inactive EGFR TKD and proposed that erlotinib is capable of 
binding to both forms with similar binding efficacy. Our simulation results illuminate the 
complexity of inhibitor binding in EGFR TKD and highlight the importance of targeting 
erlotinib and other inhibitors to different conformations of the kinase. 
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3.2 Methods and Materials 
3.2.1 System preparation and molecular docking 
Protein structures were taken from the Protein Data Bank: the active conformation of the 
wildtype EGFR TKD was modeled on 1M17 [248] and 2ITX [284] and the L834R model 
was built using the 2ITV structure [284]. The inactive EGFR TKD was modeled based on 
the 2GS7 [288] and 1XKK [276] structures. Initial erlotinib conformation was also taken 
from the 1M17 structure. Protein and ligand conformations were prepared using the 
protein preparation wizard and the “LigPrep” tools available within the Schrödinger 
computational chemistry package[224]. All simulations using Schrodinger were 
performed with the OPLS force field[137] . In particular, the docking simulations were 
performed using Schrödinger‟s Induced Fit Docking (IFD) package [236]. With the 
induced fit docking protocol, the ligand was first docked to a rigid protein conformation 
using Glide XP [98]; for the resulting top 20 complex conformations, the protein side 
chains residues within 5.0 Å of the ligand poses were subject to conformational search 
and minimization using the prime structure prediction method [129, 130]; finally the 
ligand was re-docked to the 20 new receptor conformations. Therefore, this docking 
protocol includes possible binding modes of ligands as well as the associated 
conformational reconfiguration within the receptor active site.  
3.2.2 Parameterization of erlotinib 
The resulting conformations from induced fit docking were analyzed using molecular 
dynamics simulations and the CHARMM27 forcefield [93], which consists of the 
following terms: 
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, where,    ,   ,     are the bond, angle and dihedral force constants; the 
  ,   ,   represent the equilibrium value of bond, angle and dihedral;    
   and ij are, 
respectively, the distance between atoms i and j at which the LJ potential is zero and the 
depth of the LJ potential well for the same pair of atoms; D is the effective dielectric 
constant and iq  is the partial atomic charge on atom. Since the CHARMM27 force-field 
did not contain the parameters for erlotinib, all these parameters had to be defined for 
each atom type of erlotinib (see Figure 3.1).  
The atom types describing the erlotinib molecule are shown in Figure 3.1. 9 new atom 
types were added to the CHARMM topology file. Initial partial atomic charges ( iq ) were 
calculated using CHarges from ELectrostatic Potentials using a Grid based method 
(CHELPG) [33] in the ab-initio electronic structure package GAUSSIAN, by fitting the 
molecular mechanics-derived electrostatic potential to that obtained quantum 
mechanically. The van der Waals constants (   
   and ij ) were transferred from existing 
CHARMM parameters and were not modified during refinement as their values depend 
mostly on atomic properties and are assumed to be transferable to the molecular 
environment. The equilibrium constants ( 0b ,0 ) were obtained from optimized structures 
of the small molecules based on the crystal conformation [248] using geometry 
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optimization in ab-initio calculations, and were also not changed during refinement. An 
initial guess, based on an analogy with other existing CHARMM parameters is made for 
all missing intermolecular force field constants 
bK , K , K , and the equilibrium 
constants for the dihedral terms, namely, n , and  . In particular, for the carbon-carbon 
triple bond, we first performed ab-initio potential energy surface scan along the bond 
length, then use parabolic potential function to fit the potential surface and get initial 
estimation of this bond constant. 
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Figure 3.1 Atom type defined for erlotinib. New atom types are shown in blue. 
Partial atomic charges ( iq ) were adjusted to reproduce interaction energy and geometry 
of H-bond donor/acceptor atoms in the inhibitor compound with water molecules (Figure 
3.2). The hydrogen bonded complexes shown in the figure were individually optimized 
via ab-initio calculations using the 6-31G* basis set with fixed monomer geometries. The 
partial atomic charges in CHARMM are manually adjusted to reproduce the ab-initio 
results for the geometry and energy. Following the strategy for generating the CHARMM 
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force field [93, 166, 189] , the ab-initio interaction energies are scaled by 1.16 and the 
distances are offset by -0.2 Å.  
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Figure 3.2 Water interactions used to refine the force field. 
The force constants    ,    and,     were refined by reproducing the vibrational 
eigenvalues and eigenvectors from ab-initio calculations following the procedure 
employed by Viana et. al. [263], which ensured that both vibrational frequencies and 
vibrational modes (defined by eigenvectors) calculated from CHARMM and those from 
ab-initio methods match closely. In the algorithm, the current parameter set is used for 
energy minimization and the calculation of normal modes C
i  and
c
i   (eigenvalues and 
eigenvectors) with CHARMM. Each of the modes is projected to the eigenvector sets 
G
j  
(the corresponding quantity calculated from Gaussian) and a best projection, (mode i in 
CHARMM projecting to mode maxj  in GAUSSIAN), is obtained according to two 
criteria: (1) there is a one-to-one correspondence of the two-sets of eigenvectors, and (2) 
1
max ( )c Gi j i j 
  is a minimum. Then, the penalty function value is calculated by: 
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, which implies that the CHARMM parameter set can perfectly reproduce the frequency 
spectrum from GAUSSIAN.  
For the dihedral potential surface fitting, relaxed potential surface scan for key dihedral 
angle (C4-C4-N1-C6) is performed by both CHARMM and GAUSSIAN and defined as
CD , GD  and the penalty function is defined as 2
1
( )
NGRID
C G
i i
i
D D

 
.  
 
Figure 3.3 Optimization of the merit function based on a genetic algorithm. 
An automated procedure using a genetic algorithm (GA) [178] is developed for the 
refinement of the intermolecular force field constants and the dihedral potential energy 
surfaces. The efficiency of the GA algorithm is showed in Figure 3.3 . We iteratively 
repeat the procedure to refine 1) partial charges; 2) frequencies and eigenvectors; and 3) 
the dihedral surface scan until reaching a force field with which, the target data – the 
water interaction, the dihedral potential energy surface, and the vibrational normal modes 
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– calculated by CHARMM matches well with the corresponding values calculated by 
Gaussian.  
 
Figure 3.4 Target data matching between electronic structure (Gaussian) and molecular mechanics 
calculations (CHARMM). A: one-to-one correspondence of frequencies. The frequencies are matched 
based on eigenvectors. B: dihedral scan. 
An empirical parameter set for erlotinib optimized to be consistent with the CHARMM27 
force field set (see Table 3.2 and Figure 3.4) was developed by following the procedure 
described above. This parameter set was employed in molecular dynamics simulations.  
3.2.3 Molecular dynamics simulations 
The conformations resulting from induced fit docking were minimized and subsequently 
equilibrated by performing molecular dynamics simulations. Each system was subjected 
to a constant temperature and constant pressure molecular dynamics run at 300 K and 1 
atm followed by a 10 ns constant temperature equilibration at 300K with periodic 
boundaries enforced and long-range electrostatics taken into consideration.  
Table 3.2 Water-erlotinib interactions and erlotinib dipole moment calculated by ab-initio (Gaussian) and 
CHARMM. The ab-initio interaction energies in the table have been scaled by 1.16 (See text) and the 
distances are scaled by -0.2 Å.   
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Hydrogen bond 
Interaction Energies (Kcal/mol) Distances (Å) 
GAUSSIAN CHARMM 
GAUSSIA
N 
CHARMM 
N2…HOH -6.69 -6.61 1.93 1.91 
N3…HOH_2 -5.33 -5.30 2.12 2.01 
N1H…OHH_2 -6.52 -6.52 2.44 2.63 
Dipole moment 
(Debye) 
GAUSSIAN  CHARMM 
4.87 5.07 
 
3.2.4 MMPBSA calculation 
We employed MMPBSA [102, 117, 150, 153, 231, 253, 266] to calculate the absolute 
binding free energy and compared it to the glide score. MMPBSA Energies of each 
modeled complex conformation were calculated as the average of single point MMPBSA 
energy of 500 snapshots taken from the 10 ns of the simulation. Waters and ions were 
removed from the trajectory before calculation. The molecular mechanics energy, UMM, 
was evaluated by averaging energies over all structures using an infinite cutoff for non-
bonded interactions. The electrostatic contribution to the solvation free energy, WPB, was 
calculated with Poisson-Boltzmann Solver in CHARMM [126]. The reference system 
had a solvent dielectric of 1 and 0 M salt concentration and the solvated system had a 
dielectric of 80.0 and 100 mM salt concentration. Non-polar contribution to solvation free 
energy, WSA, was approximated with the suface area model WSA=[0.00542 
kcal/mol/Å
2
]SASA +0.92 kcal/mol [215], where the molecular surface area (SA) was 
estimated with a 1.4 Å slovent probe radius. Vibrational entropy changes were neglected.  
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3.2.5 Free energy perturbation (FEP) 
We designed a thermodynamic cycle shown in Figure 3.5 to directly calculate binding 
free energy changes using FEP. To calculate the binding free energy change       , 
we calculated the difference between the free energy changes caused by mutation in the 
bound state (   ) and the unbound state (   ). The binding free energy change due to 
the mutation is obtained as                              . 
 
Figure 3.5 Thermodynamic cycle for the calculation of binding free energy change of ligand/substrate due 
to  mutation 
The free energy changes caused by the particular mutation in the bound state (   ) and 
the unbound state (   ) were calculate by free energy perturbation (FEP) method [171, 
204, 205] . The FEP procedure was performed using the alchemical method in NAMD 
2.7b2 using the dual-topology paradigm. For each state (bound or unbound), we 
performed FEP calculation in both the forward and backward direction to ensure 
convergence and define an error bar. For each direction, the perturbation was divided into 
72 windows (λ= 0, 10-6, 10-5, 10-4, 10-3, 10-2, 0.005, 0.01, 0.015, 0.02, 0.03-0.1 at an 
interval of 0.01, 0.1-0.9 at an interval of 0.02, 0.9- 0.98 at an interval of 0.01, 0.098, 
0.0985, 0.099, 0.995, 0.999, 0.9999, 0.99999, 0.999999, 1). In each window, the system 
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was equilibrated for 20 ps and run for another 100 ps for data collection. Larger window 
sizes and longer simulations have also been tested and the current setup yields reasonable 
convergence in the final binding affinity. To avoid the “end-point catastrophes”, a soft-
core potential was used to gradually scale the unbounded interaction potential. The 
scaling of van der Waals (vdW) and electrostatic interactions were handled separately. 
For appearing atoms, vdW interactions are linearly coupled to the simulation from λ=0 
(fully decoupled) to λ=1 (fully coupled) and electrostatic interactions are coupled over 
the range of λ=0.5 to λ=1. For vanishing atoms, the vdW interactions are linearly 
decoupled from the simulation over the value range of 0 to 1, and the electrostatic 
interactions are decreased gradually from λ=0 to λ=0.5. 
3.3 Results 
3.3.1 Erlotinib binds to wildtype and L834R with similar modes and 
affinities. 
The crystal structure of erlotinib bound to wildtype EGFR TKD was solved in 2002 
[248]. As a control, we first docked erlotinib to two wildtype EGFR TKD conformations 
using Glide: one from the exact crystal complex (1M17) [248] and  another from a 
crystallized EGFR TKD with the presence of ATP analog (2ITX) [284]. In both cases, we 
predicted the compound in a very similar orientation compared to the crystal 
conformation (Figure 3.6). The quinazoline moiety forms one hydrogen bond with 
residue Met769 of the kinase and the distances between N2 of the quinazoline and the 
amide nitrogen of Met769 are 2.9 Å in both the predicted structures, close to that in 
crystal structure (2.7 Å). The acetylene moiety extends to the back of the ATP binding 
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pocket, surrounded by the side chains of the Leu764, Lys721 and Thr766. Although the 
“tails” of the compound in our predicted conformation do not overlapped with those in 
the crystal structure, the differences are not significant, as the tails project into the solvent  
and do not make significant contacts with the protein residues. 
 
Figure 3.6 The docked conformation of erlotinib bound to wildtype (blue) and L834R mutant (orange) 
EGFR TKD compared with the crystallized complex of erlotinib and wildtype EGFR TKD (green).  
We then prepared the complex structure of erlotinib with L834R system by docking the 
inhibitor to L834R EGFR TKD (PDBID: 2ITZ). The best predicted conformation is 
shown to align very closely  to that of the wildtype (Figure 3.6) with the „tails‟ projecting 
into solvent and the aniline moiety binding in the pocket formed by Leu764, Lys721 and 
Thr766. The distance between N1 of the quinazoline and the amide nitrogen of Met769 is 
3.15 Å, which is within the hydrogen bonding distance. 
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Figure 3.7 Monitoring of root mean squared deviation (RMSD) of erlotinib and key distances between 
EGFRTKD, erlotinib as well as water molecules in a 10 ns molecular dynamics simulation. Data from the 
first 2 ns (pre-equilibration) are not shown.  
In both wildtype and L834R mutant systems, the erlotinib conformation is stable in the 
predicted position during the entire course of the 10 ns simulation. The hydrogen bond 
between quinazoline and Met769 in the wildtype and mutant system were found to 
fluctuate around an average value of 3.17 Å for wildtype and 3.13 Å for L834R mutant 
(Figure 3.7). The aniline moiety remains in the pocket of the Leu764, Lys721 and thr766 
during the dynamics simulation while the two tails of the erlotinib are seen to be flexible 
in both systems. 
Table 3.3 Distances between donor and acceptor atoms in the water mediated hydrogen bond network (all 
distances have a units of Å) 
Distances W1-
Erlotinib 
W1-
T830 
W1-
T766 
W1-
W2 
W2-
T766 
W2-
Q767 
W2-
Erlotinib 
Wildtype 3.25 3.12 3.50 2.96 3.56 2.90 4.20 
L834R 3.40 2.83 4.38 2.86 2.95 2.85 4.03 
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Figure 3.8 Two typical water mediated networks in the erlotinib / EGFR TKD complex.  
In the crystal structure (PDBID: 1M17), one bound water molecule is resolved, which is 
described as bridging the gap between Thr766 and the quinazoline nitrogen atom (N3). In 
our MD simulations, two water molecules were found to enter the (back) pocket for ATP 
binding and formed a stable hydrogen bond network between erlotinib and residues 
Thr830, Thr766 and Gln766 after the initial 2 ns of equilibration. The average distances 
between donors and acceptors in the networks for both wildtype and L834R are described 
in Table 3.3 and the fluctuations are depicted in Figure 3.7. We also depict two typical 
hydrogen networks in Figure 3.8A&B. In both networks, the first water molecule (W1) 
bridges the N3 atom of erlotinib, Thr830 and the second water molecule (W2) interacts 
with Gln767. In network A, W2 interacts with Thr766 while in network B, W1 interacts 
with Thr766. The two networks were found in both wildtype and L834R systems. While 
they were seen to be equally favored in wildtype system, the L834R system showed a 
preference for network A, which can explain the differences in the average values of W1-
Thr766 and W2-Thr766 distances in Table 3.3. A similar conclusion of  two-water-
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mediated interactions between erlotinib and EGFR TKD has also been reported in an 
earlier study involving a different force field [12].  
Table 3.4 Binding affinities calculated by Glide, MMPBSA and FEP for wildtype and L834R system.  
 
Glide Score 
(kcal/mol) 
MMPBSA Score 
(kcal/mol) 
FEP 
(kcal/mol) 
Wildtype -9.34 -28.2 
 
L834R -9.35 -30.7 
 
ΔΔG -0.01 -2.5 0.831±1.158 
 
To compare the binding affinities of erlotinib to wildtype and mutant EGFR TKD, we 
provide the absolute binding energy calculated using Glide and MMPBSA in Table 3.4. 
Both the Glide docking scores as well as the MMPBSA energies are very similar in 
wildtype and L834R. We also report the difference in relative binding free energy 
computed based on the thermodynamic cycle in Figure 3.5 and FEP calculations. In the 
FEP calculation, the free energy difference between the wildtype and the L834R system 
for the bound and unbound state were calculated in both forward and backward directions 
of FEP integration in order to obtain a convergence measure.  The cumulative free energy 
differences are shown in Figure 3.9 and the resulting         values are 0.68 kcal/mol 
and 0.98 kcal/mol in the forward and backward directions, respectively; thus, the FEP 
calculations yield an average of 0.83±1.16 kcal/mol in the free energy difference between 
the wildtype and the L834R systems.  
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Figure 3.9 Cumulative free energy (kcal/mol) calculated for bound and unbound systems in both forward 
and backward directions. . 
3.3.2 Erlotinib interacts with the inactive EGFR TKD 
It has been established that specific kinase inhibitors can target different forms of the 
same enzyme [151, 217]. In EGFR TKD, erlotinib has been crystallized with active 
wildtype EGFR TKD, based on which it is assumed widely that erlotinib is more 
effective in inhibiting the activated EGFR kinase. To challenge this notionHere, we 
explore the possibility for erlotinib to bind with the inactive EGFR TKD.  
 
Figure 3.10 The docked erlotinib conformation to wildtype inactive EGFR TKD. 
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The docked conformation of erlotinib to wildtype inactive EGFR TKD is shown in 
Figure 3.10. The conformation is very similar to that presented in the active EGFR TKD, 
with the same orientation and the critical hydrogen bond between N2 of erlotinib and 
Met769. This conformation has also been verified to be stable in 10 ns MD simulations. 
Besides the two water molecules present in the active kinase, there is a third water 
molecule entering the back pocket to fill the void formed by Met742, Leu753, Thr766, 
Thr830, Phe832 and Leu834, where the 3-fluobobenzyloxy group of the lapatinib 
overlays in the crystal structure (PDBID: 1XKK). The erlotinib conformations (after 10 
ns MD simulations) in both active and inactive wildtype EGFR TKD were aligned based 
on EGFR TKD backbone, see  Figure 3.11. Except for the additional water molecule, 
erlotinib has a very similar binding mode in both kinase conformations. Morever, the 
glide score for erlotinib binding to inactive TKD is 9.72 kcal/mol, which is very close to 
that for the the active form of EGFR TKD, namely 9.34 kcal/mol.  
 
Figure 3.11 Comparison of erlotinib conformations in active and inactive EGFR TKD.  
3.4 Discussion 
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Mutations in the EGFR TKD, including the point mutation L834R, have been identified 
in approximately 10% of human non-small cell lung cancer cases which confer the 
patient response to be very sensitive to treatment with erlotinib. Several factors contribute 
to the effects of mutations on the kinase inhibitor efficacy, at the core of which is changes 
in the inhibitor binding. To address this question, the Ki values of erlotinib binding to 
wildtype and mutant EGFR TKD have been reported by several groups. Some groups 
have reported similar Ki values for erlotinib (or Gefitinib, an inhibitor with very similar 
clinical and biochemical properties to erlotinib) forin both wildtype and mutant systems 
[83, 101]. However, others  have reported higher binding affinities for the L834R EGFR 
TKD relative to Wildtype [284], even though the crystal structures of gefinitib with both 
wildtype and L834R mutation EGFR TKD show no conformational differences in 
inhibitor binding.  
The structure of the wild-type EGFR TKD has been determined in both active and 
inactive conformations. The crystal structure in complex with erlotinib [248] reveals an 
active conformation of the kinase, while the structure of wild-type EGFR kinase in 
complex with lapatinib [276] shows the kinase adopting an inactive conformation. Hence, 
it is widely believed that erlotinib is more effective at inhibiting the activated EGFR 
kinase and that lapatinib is more effect at inhibiting the inactive EGFR TKD.  
Considering the different conformational preferences of the kinase inhibitors, the 
dynamic equilibrium between the active and inactive conformations of the ErbB kinase 
domains may have an important role in determining their sensitivity to these inhibitors. It 
has been proposed that Leu834 plays an important role in stabilizing the inactive 
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conformation of the EGFR kinase domain and mutation L834R likely destabilizes the 
inactive conformation and shifts the equilibrium toward the active conformation, hence 
leading to possible kinase activation as well as higher sensitivity to erlotinib [284]. 
Therefore, one possible explanation is that this increase in affinity for gefitinib results 
from the stabilization of the active-like conformation of the EGFR TKD due to mutation. 
Hence, a detailed mechanistic picture of how erlotinib binds to different EGFR kinase 
conformations and how the mutation will affect the binding in each conformation is 
necessary.  
Most of the experimental data have also dealt with the total population of EGFR kinase 
and not the relative fractions of active and inactive states. Computational analysis and 
simulations are therefore a vital complement to experiments in defining the equilibrium 
between the conformational states. Our results confirmed that the L834R mutation does 
not significantly change the inhibitor binding free energy to EGFR TKD in the active 
form. Moreover, we have shown that it is very likely that erlotinib binds to the inactive 
EGFR TKD with similar affinity as that to the active EGFR TKD. This finding highlights 
the importance for future investigations to address the effects of different kinase 
conformations on the inhibitor binding as well as inhibitor sensitivity.  
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Chapter 4 A Multiscale Computational Approach to 
Dissect Early Events in EGFR Mediated Differential 
Signaling and its Relevance to Oncogenic 
Transformations 
4.1  Introduction 
It is well established that alteration or over expression of EGFR is correlated with a 
variety of clinical cancers [173, 233].  Hence, small molecule receptor tyrosine kinase 
inhibitors for EGFR TKD are also of significant interest as cancer therapeutic drugs. 
Small molecule tyrosine kinase inhibitors (e.g., anilinoquinazoline compounds such as 
gefitinib and erlotinib), which are ATP analogues [9, 10, 134, 179, 210], have been 
shown to exhibit growth inhibitory effects against a wide variety of human tumors [57, 
58, 60, 59, 61]. The RTK inhibition approach has shown promise in some clinical trials, 
but results have been quite mixed [66]. In particular, despite the promise in a small 
(demographic) sub-population with significantly advanced disease, clinical responses to 
gefitinib and erlotinib varied among population samples. Recently, somatic mutations 
L834R, L837Q, G685S, del L723-P729 ins S (there is an alternate clinical numbering 
scheme used in the literature with an offset of 24 residues according to which these 
mutations are denoted by L858R, L861Q, G719S, del L747-P753 ins S) in the EGFR 
TKD domain were reported to correlate with the clinical response of gefitinib and 
erlotinib [48, 49, 165, 186]. In vitro, these EGFR mutants demonstrated enhanced 
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tyrosine kinase activity in comparison to wildtype EGFR and increased sensitivity to 
inhibition [10, 55, 69, 70, 165, 186, 187, 247].  
Although, the underlying biochemical basis involving the drug sensitivity to the 
mutations is still not clear, the remarkable sensitivity of cell lines carrying gefitinib 
sensitizing mutants appears not to be centered around inhibitor or ATP binding affinities, 
but rather on other biochemical mechanisms regulating the EGFR TKD activity and 
EGF-mediated signaling [107]. In a recent review, the ERbB signaling network is likened 
to a bow-tie-configured, evolvable network, displaying modularity, redundancy, and 
control circuitry [63]. Under this framework, identifying the role and significance of drug 
sensitizing mutations of ErbB receptors would require a systems level understanding of 
the signaling network [131-133]. This would prove to be of enormous value in effectively 
designing kinase inhibitors in development for cancer therapy to target many points along 
the signaling pathway simultaneously [83, 135]. Evidence emerging from biochemical 
studies points to differential phosphorylation rates associated with different tyrosine 
phosphorylation sites in the receptor [7, 139, 247, 273]. Moreover, recent structural 
studies have indicated that the clinically identified mutations are able to alter the 
regulatory elements within the receptor such as bypassing the dimer-mediated activation 
step leading to constitutive activity. Therefore, implications of the effect of such 
mutations on preferential signaling can be crucial in shaping the signaling response in 
altered cell lines derived from cancer patients.  
In this chapter, we adopt a multiscale modeling approach to study EGFR mediated 
differential signaling. Through these modeling approaches, we are able to extend the 
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prior modeling of EGF-mediated signal transduction by considering specific EGFR TKD 
docking interactions mediated by differential binding and phosphorylation of different C-
terminal peptide tyrosines on the RTK tail. By modeling signal flows through branching 
pathways of the EGFR TKD resolved on a molecular basis, we are able to transcribe the 
effects of molecular alterations in the receptor (e.g., mutant forms of the receptor) to 
differing kinetic behavior and downstream signaling response. We then extended this 
approach to study the effects of EGFR inhibition through TKIs. By employing molecular 
docking in combination with network modeling, we are able to quantify changes in the 
EC50 of receptor phosphorylation (i.e. 50% inhibition in the cellular context), and EC50 
for the inhibition of downstream markers (ERK and Akt) upon treatment with the TKI 
erlotinib, in cell-lines carrying both wildtype (WT) and mutant forms of the receptor. 
Based upon our results, we conclude that the remarkable efficacy of the inhibitor erlotinib 
in the L834R mutant cell line can be attributed to relative gain in efficiency over the WT 
in inhibiting the Akt response. 
 
Figure 4.1 Scheme for hierarchical multiscale simulations.  
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4.2 Methods 
4.2.1 Overall method description 
A hierarchical multiscale computational approach (showed in Figure 4.1) based on 
molecular dynamics simulations, free energy based molecular docking simulations, and 
deterministic network-based kinetic modeling is utilized to study EGFR mediated 
differential signaling network.  
4.2.2 Signal transduction 
 
Figure 4.2 Phosphorylation model for EGFR. (v1) EGF binds reversibly to EGFR, which increases the 
receptor‟s affinity for other ligand-bound receptors (v2). Basal levels of spontaneous dimerization also 
occur (v3, v4; not shown). ATP binds reversibly to the catalytic site of the receptor (v5). The transient 
ATP-bound EGFR must then encounter a free unphosphorylated peptide on either cytoplasmic tail in a 
diffusion-limited step (v8 – v11). (v12) The receptor catalyzes autophosphorylation at either Y1068 or 
Y1173 (for clarity, only the Y1068 site is shown). Reactions with an asterisk denote more than one reaction 
involving similar kinetics but differing substrates (see Table 4.1). 
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Table 4.1 Reaction mechanisms and parameterization for EGFR phosphorylation reactions 
Reaction Mechanism Parameter values References 
v1 [EGFR] + [EGF]  [EGFR:EGF] 
kf  = 3 • 10
-7
 M
-1
 
s
-1
 
kr  = 3.8 • 10
-3
 
s
-1
 
[143] 
v2 
[EGFR:EGF] + [EGFR:EGF]  
[EGFR2] 
kf  = 1 • 10
-7
 M
-1
 
s
-1
 
kr  = 0.1 s
-1
 [143] 
v3
 a
 [EGFR] + [EGFR]  [EGFR2] 
kf  = 1 • 10
-7
 M
-1
 
s
-1
 
kr  = 1 • 10
 3
 
s
-1
 
[143] 
Modeled 
v5
 b
 [EGFR2] + [ATP]  [EGFR2:ATP] 
Km  = 2.4 • 10
-8
 
M
-1
 
 [34] 
v8
 c
 
[EGFR2:ATP]  
[EGFR2:ATP:Y1068] 
kf  = 6.51 • 10
5
 s
-1
 kr  = 769 s
-1
 
[85],  
Modeled 
v10
 d
 
[EGFR2:ATP]  
[EGFR2:ATP:Y1173] 
kf  = 1.98 • 10
5
 s
-1
 kr  = 48.1 s
-1
 
[85], 
Modeled 
v12
 e
 
[EGFR2:ATP:Y1068]
[EGFR2
Y1068-P
] 
kcat  = 0.29 s
-1
  [85] 
v14
 f
 
[EGFR2:ATP:Y1173]
[EGFR2
Y1173-P
] 
kcat  = 0.25 s
-1
  [85] 
v16
 g
 [EGFR2
Y1068-P
]  [EGFR2] 
Vmax  = 4.5 • 10
-7
 
M s
-1
 
Km  = 5.0 • 
10
-8
 M 
[143] 
a
 An identical rate equation was employed for spontaneous dimerization of EGFR and EGFR:EGF (v4) 
b
 Identical rate equations were employed for ATP binding to EGFR2
Y1068
 (v6) and EGFR2
Y1173
 (v7) 
c
 An identical rate equation was employed for Y1068 binding to EGFR2
Y1173-P
:ATP (v9) 
d
 An identical rate equation was employed for Y1173 binding to EGFR2
Y1068-P
:ATP (v11) 
e
 An identical rate equation was employed for phosphorylation of EGFR2
Y1173-P
:ATP:Y1068 (v13) 
f
 An identical rate equation was employed for phosphorylation of EGFR2
Y1068-P
:ATP:Y1173 (v15) 
g
 Identical rate equations were employed for dephosphorylation of EGFR2
Y1173-P
 (v17) and EGFR2
Y1173-P
 
(v18) 
 
EGF stimulation in a cell results in the simultaneous activation of multiple pathways that 
are functionally interlinked [139, 218, 219]. The major pathways we included in this 
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chapter are EGF-ERK route and PI3K-Akt pathway. In the EGF-ERK pathway, the 
activation of Ras initiates a multistep phosphorylation cascade that leads to the activation 
of MAPKs, ERK1, and ERK2 [234]. ERK1 and ERK2 regulate transcription of 
molecules that are linked to cell proliferation, survival, and transformation. The PI3K-
Akt pathway results in the activation of the downstream protein-serine/threonine kinase 
Akt. Prior studies have established that some growth hormone-stimulated membrane 
tyrosine kinase receptors interact with Shc adapter protein and phosphatidylinositol3'-
kinase (PI3K), and consequently PI3K-activated Akt inhibits Raf-1 and the following 
ERK activity [39, 47, 111, 211]. Akt transduces signals that trigger a cascade of 
responses from cell growth and proliferation to survival and motility [174, 197, 214, 
234]. The pathways we do not include in our model are phosphoinositol metabolism and 
signaling [20, 21, 114, 262, 272], activation and nuclear translocation of STATs [23, 25, 
148, 277], clathrin-mediated endocytosis [75, 265] and molecular cross-talk with other 
receptor systems [27, 45, 90, 144, 163, 194, 195].  
In the kinetic model employed here, signaling through the EGFR is modeled by 
combining three published models and augmented by our own set of reactions and 
calculations (see Figure 4.2 and Table 4.1). Phosphorylation and docking reactions are 
modeled according to Ref. [143]; the MAP kinase pathway reactions are modeled after 
Ref. [223]; Akt and PI3K activation are incorporated into the model as described in Ref. 
[39]. The similar parameterization and topology in these models allows us to construct a 
consistent, stable, and comprehensive system with results in good agreement with 
published experimental data [216]. Altogether, our model comprises of 74 reactions and 
67 species. 17 of these reactions are novel and represent enhanced molecular resolution 
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and detail in EGFR activation, phosphorylation, and docking reactions (Figure 4.2 and 
Table 4.1).  We note that we restrict our models to the early signaling phase (before 
receptor internalization) and thus our model does not take into consideration receptor 
signaling from endosomal compartments [115, 112, 113]. 
Receptor Dimerization. Ligand-bound receptors associate into dimers in a diffusion-
limited step [143] with a second-order forward rate constant of 0.1 M
-1
 s
-1
 and a reverse 
rate of 0.1 s
-1
 (v2 in Table 4.1). To account for the observed basal levels of 
autophosphorylation in the absence of an agonist [54], we also implemented reactions in 
which unactivated EGFR can form homo- or heterodimers with other inactivated or 
activated receptors (v3, v4 in Table 4.1). Assuming a dissociation constant of 0.1 mM, 
we estimate the reverse rate for these reactions (kr,3,4 = 1000 s
-1
) to be 10,000-fold greater  
than that of two activated receptors. 
Receptor Phosphorylation. In our model, the phosphorylation of the receptor occurs in 
three steps: (1) ATP binds reversibly to the active site of EGFR (v5-v7 in Table 4.1). The 
wildtype Km = 24 nM reported by [34] was used for this reaction. (2) An 
unphosphorylated tyrosine peptide on the cytoplasmic tail diffuses and binds transiently 
to the active site (v8-v11 in Table 4.1). Peptide dissociation rates were parameterized 
according to values reported in the literature [85]. The reverse rate for these reactions was 
estimated by setting koff = (kon) • e
+G/kT, where ΔG was calculated from the Km for each 
peptide. (3) In the third step, a phosphate group from ATP is transferred to either Y1068 
or Y1173 (v12-v15). kcat values of 0.29 s
-1
 and 0.25 s
-1
 were used for catalysis of Y1068 
and Y1173, respectively [85]. By undergoing two rounds of phosphorylation, a single 
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receptor may be phosphorylated at both sites. Phosphorylation reactions and parameters 
are listed in Table 4.1. 
Docking interactions. Differential signaling is modeled by allowing only a subset of 
signaling proteins to bind to each form of the phosphorylated receptor (Figure 4.2). Using 
the most comprehensive model of network interactions to date [184], we partition 
signaling proteins into two groups. Grb2 and PI3K bind only to Y1068; PLCγ and Shc 
bind only to Y1173  [139, 247]. Higher order docking reactions are modeled as described 
previously [39, 143, 223]. 
Inhibition reactions. To model competitive inhibition by an ATP analog, we added the 
reaction EGFR + inhibitor  EGFR:inhibitor in our model. The inhibition constant (KI) 
of erlotinib for WT ( 17.5 nM ) and L834R ( 6.25 nM ) receptors are obtained by 
obtained from published experimental data [48].  
The complete model is assembled and analyzed using the Systems Biology Toolbox for 
MATLAB (http://sbtoolbox.org/). Simulations are carried out using the CVODE solver 
from Sundials (http://www.llnl.gov/CASC/sundials) along with a compiled version of the 
model.  
4.2.3 Molecular dynamics (MD) 
An active conformation of the wildtype EGFR TKD domain is modeled using the 1M17 
structure [248, 288] by adding hydrogen atoms and missing residues using the 
CHARMM [37] biomolecular simulation package. The resulting conformations are first 
energy minimized and subsequently equilibrated by performing molecular dynamics. A 
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L834R mutant active structure was also generated on the basis of the wildtype structure 
(mutation performed using the INSIGHT II package [4]) and subsequently energy 
minimized using CHARMM. The proteins are then solvated and neutralized by placing 
ions; the solvated models are minimized and equilibrated using the NAMD program [182] 
with periodic boundaries enforced and long-range electrostatics taken into consideration. 
Each system is subjected to a constant temperature and constant pressure molecular 
dynamics runs at 300 K and 1 atm followed by constant temperature equilibrium at 300K 
for 10 ns.  
4.2.4 Molecular docking  
Molecular docking is used to predict ligand binding in the absence of a ligand-bound 
crystal structure and functional affinity data. We employ AutoDock, an automated 
docking tool designed to predict how small molecules, such as substrates or drug 
candidates, bind to a receptor of known 3-dimensional structure [178]. We perform a 
global conformational search using a multiple conformation docking strategy, in which 
the protein flexibility is taken into account implicitly by using multiple conformations, 
i.e., by sampling from several (100) frames of the 10 ns molecular dynamics trajectory. 
The lead docked conformations (based on lowest binding free energy) are extracted and 
clustered on the basis of their root-mean-squared deviation or RMSD values.  
As control simulations, we validated the predicted results of our docking protocol by 
applying our method to study ligand binding to enzymes for which a solved crystal 
structure of the bound complex was available. In all three cases, namely ATP binding to 
cAMP, ATP binding to insulin receptor kinase, and erlotinib binding to EGFR TKD, the 
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predictions of the location and conformation of the bound ligand matched the 
crystallographic data very closely (data not shown). This multiple conformation docking 
protocol is employed in calculating the ATP, inhibitor, and Y1068/Y1173 peptide 
substrate binding affinities. 
4.3 Results 
4.3.1 Substrate binding affinities for EGFR TKD.  
 
Figure 4.3 Binding modes for ATP (cyan) and the optimal peptide sequence (yellow) in the EGFR TKD 
domain. The geometry of the active site is consistent with that prescribed for an ideal two-metal-ion 
catalyzed mechanism and reveals a state that is poised for the phosphoryl transfer reaction. The alignment 
of the two divalent Mg2+ ions as well as the catalytic aspartates D813 and D831 are also shown. 
In order to explore the C-terminal peptide-substrate-bound pre-catalytic conformation, we 
dock EGFR TKD substrate peptides to the catalytic site. First, we focus on an optimal 
peptide sequence EEEEYFELV as a control. This optimal sequence is selected for a 
maximal value in kcat/KM among EGFR TKD substrate peptides [246]. Based on 500-
A-loop
Tyrosine in Peptide
ATP
MG2+
D831
Catalytic 
loop
D813
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1000 different genetic algorithm runs for docking of this peptide to EGFR TKD, we 
select the best binding conformation for binding as one that yields the lowest binding free 
energy simultaneously with the correct orientation for the tyrosine binding into the active 
site. The latter criterion is essential in ensuring that kcat is not significantly compromised 
in obtaining a stronger binding. We depict in Figure 4.3, the peptide conformation bound 
to the active site, which is seen to be ideally poised for a two-metal-ion catalyzed 
phosphoryl transfer from ATP to the bound tyrosine [176, 250]: i.e., the relative positions 
of the ATP, Mg
2+
 ions, and the catalytic aspartates are in good alignment. Encouraged by 
this result, we performed peptide docking simulations for two substrate peptides (each 
being seven amino acids long) corresponding to the Y1068 (VPEYINQ) and Y1173 
(NAEYLRV) sites of the C-terminal tail for both wildtype and L834R mutant structures. 
Based on similar criteria of lower binding free energy and optimal catalytic geometry, we 
calculated the peptide binding affinity corresponding to sites Y1068 and 1173 for 
wildtype and L834R mutant systems. Upon mutation, the calculated KM for the Y1068 
peptide decreased 20-fold (calculated G[wildtypeL834R]= -2.2 kcal/mol), while the 
calculated KM for the Y1173 peptide increased 4-fold (calculated 
G[wildtypeL834R]= +0.9 kcal/mol). Analysis of the binding modes reveals that the 
relative alignment of the tyrosine with respect to the catalytic site is ideal (2.2 Å in the 
observed distance  between Tyr OH oxygen and Asp 813 O2) for the two peptide 
tyrosines binding to wildtype, with the two mutant systems showing a 0-1.5 Å deviation. 
The differences can translate into differences in kcat values associated with the tyrosine 
phosphorylation. Assuming a harmonic energy profile along the reaction coordinate  
with a force constant K, the work done in reducing this distance is given by 1/2K
2
. The 
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value of K is obtained by recording the fluctuations of  in the MD simulations 
(K=kBT/
2
=0.77 kcal/mol/Å
2
 for the wildtype and 1.01 kcal/mol/Å
2 
for L834R), where 
 is the standard deviation associated with the fluctuations in  in the trajectories). The 
normalized values of kcat/KM can then be compared for the four systems at the same value 
of =2.2 Å); the relative increase in kcat/KM: 1068 for the L834R in comparison to the 
wildtype is 20-fold (increase by 1-order of magnitude), while the relative decrease for the 
1073 is 200-fold (decrease by 2-orders of magnitude). This differential sensitivity 
translates into differences in phosphorylation of the associated tyrosine sites, which 
ultimately leads to differential signaling and downstream activation in the EGFR 
network: the Y1173-phosphorylation is associated Shc mediated ERK activation and 
Y1068-phosphorylation is associated with Akt activation [139, 247]. 
4.3.2 Differential signaling through EGFR TKD 
By employing the deterministic model we have calculated transient evolution of the EGF-
mediated signaling network under a variety of initial conditions and parameter values. In 
particular, we have focused on two pools of normal ([EGFR]=100 nM or 33,000 
receptors per cell) and over expressed ([EGFR]=2000nM or 660,000 receptors per cell) 
EGFR concentrations, each in the absence (serum starved, [EGF]=0 nM) and presence 
(serum cultured, [EGF]=8 nM) of the EGF ligand. Since our molecularly resolved model 
is currently focused on differential signaling through Y1068 and Y1173 phosphorylation 
sites of EGFR TKD, we track the integrated response of ERK and Akt phosphorylation 
levels in our simulations. Each output state was quantified according to the peak level of 
phosphorylation over the simulated time of 1000 s. Specifically, we perform a two-
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dimensional scan over kcat/KM values associated with Y1068 and Y1173 phosphorylation 
in which the respective kcat/KM values are allowed to deviate from their default (wildtype) 
value over a logarithmic range of five log units. The result is a two-dimensional matrix in 
which each element represents output from a single simulation involving a unique pair of 
parameters (see Figure 4.4).  
 
Figure 4.4 Calculated ERK and Akt phosphorylation levels in units of nM (peak-levels over the time course 
of 1000 s) under serum starved (EGF-) and serum cultured (EGF+) conditions for cell types with normal 
EGFR expression and EGFR over expression. In each panel, the blue circle denotes the wildtype levels and 
the green square denotes those relevant to the L834R mutant cell lines. 
4.3.3 Inhibition of EGFR phosphorylation 
Next, we examined the sensitivity of WT and mutant systems to inhibition in the cellular 
context by calculating receptor phosphorylation over a range of erlotinib concentrations. 
Simulations were performed for both „normal‟ ([EGFR] = 100 nM) and „over-expressed‟ 
([EGFR] = 1000 nM) systems. All simulations were performed with (50 ng/ml or 8 nM) 
or without ligand (EGF) stimulation. 
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[EGFR] = 100 nM
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Figure 4.5 Relative inhibition of receptor phosphorylation. Tyr phosphorylation levels relative to that 
without inhibitor are plotted. 
The EC50 (inhibitor concentration at which 50% of the activity is suppressed in the 
cellular context; this is different from IC50 because the non-linear and temporal effects 
due to signal-transduction is accounted for) for L834R was 50-fold lower (see Figure 4.5: 
A&B) than that of the WT (100 nM vs. 5000 nM) in the presence as well as absence of 
ligand. There were also no prominent differences between the inhibition at 1068 and 
1173 sites. In over-expressed systems, there was no significant difference in EC50 among 
the four groups (Figure 4.5: C&D). All had an EC50 near 1000 nM. 
4.3.4 Inhibition of downstream activation 
The sensitivity of downstream signaling molecules ERK and Akt to inhibition for a range 
of erlotinib concentrations is shown in Figure 4.6. 
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Figure 4.6 Inhibition of ERK and Akt activation in systems with normal receptor expression. Responses 
plotted relative to that without inhibition under the same conditions. 
In normal expression systems (Figure 4.6 A&B), there was a nearly 7-fold increase in the 
efficiency of pERK inhibition for L834R (EC50 = 100 nM) compared to WT (EC50 = 700 
nM) with and without ligand present. With respect to Akt activation, there was a 4-fold 
decrease in EC50 for L834R compared to WT (300 nM vs. 1200 nM) with and without 
ligand present. For the case of over-expressed receptors (Figure 4.6 C&D), inhibition of 
pERK is 4-fold more efficient for L834R compared to WT, while pAkt inhibition is 
almost 10-fold more efficient for the L834R mutant, although significantly more erlotinib 
is required to achieve inhibition (EC50=40 μM). This result is consistent with the 
dramatically elevated Akt levels expected in systems that bear both the L834R mutation 
and a higher receptor count.  
4.4 Discussion and conclusion 
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Based on an integration of a large body of knowledge accumulated over the years, the 
modular nature of EGFR-mediated signaling has become apparent [63, 131]. Through a 
hierarchical multiscale modeling scheme, we have realized a molecular resolution to this 
system-level view, which can potentially augment our predictive as well as 
comprehensive capabilities and rationalize the changes in early signaling characteristics 
of altered and mutant cell lines. Our overall findings are summarized below. 
Our results from the free energy docking simulations suggest enhanced binding of the 
inhibitor erlotinib to the L834R mutant system in comparison to wildtype binding. Our 
results also reveal preferential binding and phosphorylation of certain C-terminal tyrosine 
substrates (but not others) to the L834R mutant in comparison to the wildtype: that is, the 
calculated change in the turn over rate (kcat/KM)  upon the L834R mutation is markedly 
different for the Y1173 peptide in comparison to the Y1068 peptide. This results in a 
differential sensitivity at the receptor level. Specifically, the estimated increase in kcat/KM  
for the Y1068 peptide is 10-fold in comparison to a decrease of 100-fold for the 
Y1173 peptide. Thus, we expect to see a net increase in phosphorylation of Y1068 and a 
net decrease in phosphorylation of Y1173 for the L834R mutant, in comparison to 
wildtype levels. The biochemical results of Sordella et al. [247] and Chen et al. [51] 
corroborate this view qualitatively; in these studies, the immunoblots measuring the 
degree of phosphorylated receptor at the Y1173 site show a modest decrease for the 
L834R mutant in contrast to a strong increase for the Y1068 site, both in comparison to 
their respective wildtype measurements. 
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Our systems level simulation illustrates how the altered affinities at the receptor level for 
the wildtype and L834R translates into changes in the downstream response. In Figure 
4.4, we explored how the variation in Y1173 and Y1068 phosphorylation affects the peak 
responses of ERK and Akt for two different EGFR concentrations, each in the absence or 
presence of EGF stimulation. The calculated responses for the wildtype values are 
highlighted by the blue circles at the origin of each of the panels. The responses for 
L834R are identified by the green square centered at a (kcat/KM)/(kcat/KM)wildtype value of 
1/100 (-2 in log10 units) for Y1073 and 10 (+1 in log10 units) for Y1068. Owing to the 
constitutively active characteristic of the L834R mutant, the signals relevant for the 
L834R system (even in the absence of EGF) are analogous to those in the panels with 
EGF stimulation. As indicated by the color maps in these two scans, increasing the 
degree of phosphorylation of the Y1173 site (positive x-direction) leads to an overall 
increase in ERK response. This finding is consistent with our model which is based on 
Y1173 being an important docking site for the Shc and Grb-2 adaptors that lead to Ras 
activation and subsequent Erk phosphorylation. For normal EGFR expression, the 
calculated ERK response in the absence of EGF is low for the L834R mutant (0.01 nM) 
but negligible (zero) for the wildtype. In the presence of EGF the ERK response for 
L834R is 7-fold lower than that for the wildtype. For over expressed EGFR, the ERK 
activation is 7-fold higher in L834R compared to wildtype both in the presence as well as 
in the absence of EGF stimulation. Thus, Erk stimulation is higher in EGFR over-
expressed cells. The Akt response relative to the wildtype is 2-fold higher for the mutant 
cells under no EGF stimulation and about the same under EGF stimulation for normal 
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EGFR expression. The Akt response does not seem to be affected by mutation for high 
EGFR expression either in the presence or absence of EGF.  
Our calculated responses for ERK and Akt signaling for normal EGFR expression agree 
with the qualitative experimental observations of Sordella et al. [247] and Tracy et al. 
[259]: namely, that the Erk stimulation levels decrease and the Akt levels are maintained 
for the mutant cells with normal EGFR expression levels. This preferential activation of 
Akt in L834R mutant cell lines observed in these experiments is consistent with the 
systems level predictions from our simulations. Moreover, our calculations predict that 
the preferential Akt activation is not featured in EGFR over-expressed cells. Through 
multiscale modeling, we have also shown how this framework can be utilized to predict 
the efficacy of the inhibition in cell-lines, especially those harboring mutations in the 
receptor. We find that the mutant cell line is more susceptible to inhibition by TKIs both 
at the level of curbing the receptor phosphorylation as well as that of downstream (ERK 
and Akt) activation. Considering that the absolute pAkt levels are 5-fold higher than 
those for pERK in the WT and 100-fold higher in the mutant, the remarkable effect of the 
drug in non-small-cell lung cancer cell lines carrying the mutation can be attributed to the 
gain in efficacy with respect to Akt inhibition. 
In light of the overall agreement between simulations and experiment, we can begin to 
explore the origins of inhibitor sensitivity in L834R mutant cell lines. The enhanced 
sensitivity of erlotinib to L834R mutant arises from a combination of several effects: (1) 
the mutant system has a higher binding affinity to the inhibitor; (2) the constitutive 
activity of L834R deems the mutant to be a more potent target for therapeutic inhibition; 
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(3) The differences in the predicted downstream response (between the wildtype and the 
mutant) accounted for by early signaling events can potentially lead to a divergent long-
term behavior in the two systems causing a differential sensitivity to inhibition.  
In conclusion, we have described the role of a hierarchical multiscale computational 
approach in resolving at a molecular level the systems-level model of EGFR-mediated 
signal transduction, to help rationalize the collective information emerging from 
biochemical, cell biology, and clinical studies. Our approach enables us to transcribe 
differences in molecular mechanisms as well as functional activity originating at the 
single molecule level into tangible differences in early signaling events. Therefore, 
subject to the well appreciated modeling limitations, this predictive capability is useful in 
differentiating signaling characteristics of mutant cell lines from the native wildtype case. 
This molecular-based refinement of the overall EGFR signal transduction model is a first 
attempt at untangling the differential nature of early signaling events triggered by 
receptor activation and their consequences in shaping the signal transduction in altered 
cell lines derived from different pathologies. A complete model, which is currently being 
pursued, will not only require resolving the differential characteristics of all of the 
tyrosine phosphorylation sites in EGFR TKD and their associated substrate recognition 
properties in EGFR, but also the extension to other Erb family members in the context of 
homo- and hetero-dimers. Transactivation of EGFR occurring through ligand-induced 
receptor heterodimerization [270] combined with a potential for differential signaling 
adds a palette of finer control elements in the ErbB-family signaling network. Indeed, 
recent studies have identified possible mutations in ErbB2 that may correlate with drug 
sensitivity in different cancers [155, 156]. The computational tools described here are 
93 
 
ideal for assessing the likely effect of novel EGFR and ErbB2 mutations and determining 
whether the drug-sensitizing mutations implicated in non-small-cell lung cancer also 
occur in other cancers. We believe that our model driven approach will in the long-term 
significantly impact the optimization of future small molecule therapeutic inhibition 
strategies. 
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Chapter 5 A Flexible-protein Molecular Docking Study 
of the Binding of Ruthenium Complex Compounds to 
PIM1, GSK-3β, and CDK2/Cyclin A Protein Kinases 
5.1 Introduction 
As the overall protein fold is conserved in the kinase family, one of the major challenges 
is to understand the molecular basis for inhibitor sensitivity and to design small-molecule 
compounds which are highly selective (specific) to the targeted protein kinase. Progress 
towards the design of selective small-molecule kinase inhibitors based on the exploitation 
of distinct features presented by ATP-binding site has recently been reviewed [258]
, 
[183]. 
Vast majority of specific enzyme inhibitors are small organic molecules that gain their 
specificity by a combination of weak interactions, including hydrogen bonding, 
electrostatic contacts, and hydrophobic interactions. Recently, a novel strategy has been 
introduced for the design of small-molecule enzyme inhibitors by using substitutionally 
inert organometallic scaffolds [31, 172], based on the hypothesis that complementing 
organic elements with a metal center may provide new opportunities for building three-
dimensional structures with unique and defined shapes. In particular, a class of half-
sandwich ruthenium complex compounds based on the scaffold shown in  Figure 5.1have 
been reported to show high affinities and promising selectivity profiles for protein 
kinases and lipid kinases [11, 32, 278].  
95 
 
 
Figure 5.1 Chemical structure of ruthenium complex compound (named compound 1 in this chapter) 
analyzed in this chapter. The R- enantiomer is depicted on the left and the S-enantiomer on the right. 
The new ruthenium complex compounds are designed to mimic the shape of 
staurosporine, a well-known protein kinase inhibitor, by replacing the indolocarbazole 
alkaloid scaffold with metal complexes in which the structural features of the 
indolocarbazole heterocycle is retained. The ruthenium metal center plays a structural 
role by organizing the organic ligands in the three-dimensional space. As shown in Figure 
5.1, the coordination geometry around the ruthenium is pseudo-octahedral, formed by the 
pyridocarbazole ligand, the CO group oriented perpendicular to the pyridocarbazole 
plane, and the cyclopentadiene (Cp) moiety. The compound was designed to bind with 
the kinase by forming hydrogen bonds to the backbone residues at the hinge region of the 
kinases. However, unlike staurosporine, which is a nonspecific nanomolar inhibitor for 
most protein kinases, these ruthenium half-sandwich compounds show remarkable 
selectivity profiles. In particular, profiling the racemic mixture of (R/S)-1 against more 
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than 50 protein kinases in vitro shows  high selectivity of this class of compounds for 
PIM1 (IC50= 3nM, 100µm ATP) and GSK-3β (IC50= 50nM, 100µm ATP)[11]. 
Interestingly, the phylogenetically and structurally closely related cyclin-dependent 
kinases (CDKs) are not significantly inhibited, with IC50= 3M (100µm ATP) for the 
CDK2/cyclin A complex [11].  
Table 5.1 Sequence alignment of residues around active site of the three protein kinases, PIM1, GSK3, and 
CDK2. Residues which are significantly different are colored. 
Kinases
PIM-1 L44 G45 S46 F49 V52 A65 I104 L120 E121 R122 - P123 E171 L174 I185 D186
GSK-3β I62 G63 N64 F67 V70 A83 V110L132 D133 Y134 V135 P136 Q185 L188 C199 D200
CDK2 I10 G11 E12 Y15 V18 A31 V64 F80 E81 F82 L83 H84 Q131 L134 A144 D145
N-terminal lobe Linker region C-terminal lobe
 
Sequence alignment analysis (Table 5.1) shows a high degree of conservation among the 
ATP binding pocket residues of the three kinases. Superposition of the kinase active sites 
using the α-carbon atoms of the residues around the ATP pocket also shows that the 
structure of the binding site is highly similar among the three kinases (Figure 5.2). 
Despite these similarities, differences in specific amino acid positions are noted (colored 
in Table 5.1 and labeled in Figure 5.2) , which possibly have a bearing on the differences 
in the binding interactions, and hence the inhibitor selectivity. 
Although it is of great interest to understand the interaction of ruthenium compounds 
with the three protein kinases in atomic details, [217, 267] only one crystal structure, i.e., 
PIM1 bound with (R)-1, is currently available. It is not clear how the other enantiomer, 
(S)-1 is bound to PIM1. The bound conformations of both (R)-1 and (S)-1 are not known 
from experiments either. In this chapter, we modeled the interactions between the 
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ruthenium scaffold and three protein kinases, PIM1, GSK-3β and CDK2/cyclin A, 
targeting the selectivity profile of the compound.  
 
Figure 5.2 Structural alignment of the ATP binding pockets of three protein kinases, PIM1, GSK3, and 
CDK2/CYCLIN A.  
Molecular docking is frequently used to predict ligand binding in the absence of ligand-
bound crystal structures and functional affinity data [36, 109]. While ligand flexibility is 
accounted for in most docking programs, many treat the protein as a rigid body. However, 
in practical scenarios in which the receptor structure is derived either from an 
experimentally determined structure of the apo- kinase or from a structure where the 
kinase is complexed with a different ligand, the rigid-receptor docking often fails to 
predict proper bound conformation. Hence, efforts have been made to account for the 
protein flexibility [50, 275]. In this chapter, we applied the ensemble docking procedure 
to predict bound conformations of ruthenium compounds (R/S)-1 against the three protein 
kinases PIM1, GSK-3β and CDK2/cyclin A. Our docking results reveal the protein-
ligand interaction and suggest possible structural factors that may give rise to different 
binding affinities of the proteins. 
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5.2 Methods 
The flow chart in Figure 5.3 depicts the ensemble docking protocol we have followed. To 
summarize, protein conformations are sampled with all-atom molecular dynamics (MD) 
simulations with explicit solvent. Charges and geometry of the ligands are calculated 
using electronic structure (ab-initio) methods. The ligands were then docked into each of 
the protein conformations using the docking program AutoDock3.0. The predicted bound 
conformations of ligand are subsequently clustered. 
 
Figure 5.3 Flow chart of ensemble docking method 
5.2.1 Ab-Initio electronic-structure calculations of Ru-complex 
compounds 
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The geometries of both enantiomers of compound 1 are optimized using the Gaussian 98 
[254] program at the Hartree-Fock (HF) [254] level. For the hydrogen, carbon, oxygen 
and nitrogen, 6-31G
*
 basis set is used while for the Ru atom, the Los Alamos ECP 
(effective core potential) plus DZ (double zeta) basis set (LanL2DZ [136]) is used. The 
geometry optimization of the molecule returns the minimum-energy geometry of the 
molecule and the spatial electron-density map at 0 K. Following the procedure of Aiken 
et.al.[6], the partial (Mulliken) charges on each atom are inferred from the ab-initio 
calculations which are used in determining the molecular descriptors of the inhibitor 
compound and are used further in the docking calculations. 
5.2.2 Protein conformation preparation 
The native and non-native protein conformations of PIM1 kinase are constructed based 
on two different crystallographic structures from the protein data bank: (1) the structure 
of the PIM1/(R)-1 bound complex (PDB ID: 2BZH), and (2) the structure of PIM1 bound 
to an ATP analog (PDB ID: 1YXT). For the GSK-3β and CDK2/cyclin A systems, 
conformations derived from crystal complex structures with the ATP analog (1I09 for 
GSK-3β and 1QMZ for CDK2/cyclin A ) are employed in the docking simulations. Four 
apo-kinase conformations are generated based on these crystal structures, by removing 
ligands and adding hydrogen atoms and other missing residues using CHARMM [37] 
biomolecular simulation package.  
To generate an ensemble of conformations for each kinase, molecular dynamics (MD) 
simulations for each protein kinase are performed with the respective crystal structures 
serving as the starting conformation. The proteins are explicitly solvated using the TIP3P 
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model for water and neutralized by placing ions (sodium and chloride) at an ionic 
strength of 150 mM. The ions are placed at positions of electrostatic extrema predicted by 
the mean-field Debye-Huckel calculations. The solvated models are energy minimized, 
heated to 300 K, and equilibrated at constant temperature and constant pressure (300 K 
and 1 atm) using the NAMD simulation package [141] in conjunction with the 
CHARMM27 force-field [166].  All our simulations are performed on a fully periodic 
system and include long-range electrostatics using the Particle Mesh Ewald algorithm 
[14]. The extent of the equilibration phase is determined by tracking the plateau behavior 
of the RMSD (root mean square deviation) of the protein calculated with respect to its 
starting conformation. For each protein kinase system, 10 ns of dynamics runs are 
generatedFor each system, we extract 100 protein conformations at uniform intervals 
from the last 8 ns of the respective trajectories for use in our ensemble docking protocol. 
In order to make the comparison of different systems easier, all the protein conformations 
are aligned with respect to the PIM1 coordinates in 2BZH structure based on residues 
within 15 Å of the ATP binding site.  
5.2.3 Docking protocol 
AutoDock3.0.5 program [178] is used for docking simulation. For each protein structure, 
the non-polar hydrogen atoms are merged to heavy atoms and Kollman charges and 
solvation parameters are then assigned to the protein atoms using AutoDockTool (ADT) 
[1]. Grid maps for each protein conformation of dimension 126126126 points with a 
grid spacing of 0.184 Å are constructed, encompassing the entire ATP binding site. The 
Lamarckian Genetic Algorithm (LGA)[178] is applied to explore the conformational 
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space of the ligand using the scoring function. In each docking run, the initial population 
is set to 50 individuals, the maximum number of energy evaluations is set to 10
8
, and the 
generation of GA run is set to 10,000. 30 GA runs are performed for each protein 
conformation. This choice for the set of run-parameters is adequate to achieve 
convergence of the docking results.  
5.2.4 Ligand conformation clustering  
Ligand conformations are clustered using the hierarchical clustering algorithm in Matlab 
[2]. For each docking run, the root mean squared deviation (RMSD) value between each 
pair of all docking-generated ligand conformations (30 for single conformation docking 
with the crystal structure and 3000 for ensemble docking) are calculated and used as the 
distance matrix to build a hierarchical tree by progressively merging clusters using 
unweighted average distance of each cluster. Then a cut-off RMSD value is used to 
cluster ligand conformations based on the hierarchical tree. We used the pairwise RMSD 
distribution of docked conformation to determine the optimal radius [152]. The 
distribution of pairwise RMSD of all the docked conformations are depicted in Figure 
5.4. The minimum RMSD values after the first peak are chosen as the optimal clustering 
radius, namely, 2.0 Å for single conformation docking and 2.5 Å for ensemble docking. 
The conformations with the lowest docked energy in each cluster are reported as the 
predicted bound conformations for each system.  
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Figure 5.4 Pairwise RMSD distribution histogram of docked conformations for PIM1/(R)-1 system. A: 
single conformation docking, B: Ensemble docking 
5.3 Results 
5.3.1 Ensemble docking protocol counts the protein flexibility and 
improves the prediction of bound complex structure 
In this chapter, we are interested in predicting and comparing the interaction between Ru-
complex compound and three protein kinases, PIM1, GSK-3β and CDK2/cyclin A to 
provide insight on structural basis of the selectivity profile of the compound. Docking 
ligand to non-native protein conformation (apo- protein or protein complexed with other 
ligands) is still a challenging task. To account for the protein flexibility, we used the 
ensemble docking protocol, i.e., docking the Ru-complex compound into an ensemble of 
protein snapshots generated by MD simulations.  
The protocol was first tested using PIM1/(R)-1 system, where a crystal structure of the 
exact complex has been solved. To examine the reliability of different docking protocols, 
we performed two test cases to dock the (R)-1 compound to the PIM1 protein kinase. The 
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first test was the docking to the PIM1 structure (PDB ID: 2BZH) in which (R)-1 was co-
crystallized. In the second test, the crystal structure of PIM1 (PDB ID: 1YXT) bound 
with an ATP analog was used instead. In each test, both the traditional docking protocol 
based on single protein structure and the ensemble-docking (using 100 conformations) 
protocol were applied to generate complex structures. The actual complex structure 
(2BZH) determined from crystallography serves as the “native” pose, or a reference to 
evaluate the docking results. 
 
Figure 5.5 RMSD relative to the reference structure versus the docked energy score for each predicted 
conformation of compounds (R/S)-1 to two PIM1 structures, i.e. the native structure of PIM1 bound to 
compound (R)-1 (PDBID: 2BZH) and the non-native structure of PIM1 bound to an ATP analog 
(PDBID:1YXT). The symbols ■ corresponds to single conformation docking results and the symbols ○ 
correspond to ensemble docking results. 
Our results in Figure 5.5 show that the predicted ligand-bound structures from single-
conformation docking can be classified into several clusters with similar dock energies. 
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When ensemble docking was used and the flexibility of the protein was thus accounted, 
more complex conformations were generated and a better discrimination between the 
lowest (dock) energy conformations of different clusters was observed. Furthermore, 
conformations similar to the native pose emerge among the top clusters when ranked by 
dock energy.  
 
Figure 5.6 Predicted bound conformations of the inhibitor with the lowest RMSD to the reference structure 
from single conformation and ensemble conformation docking are aligned together with crystal structure. 
Blue: the single conformation docking of compound (R)-1 to the native PIM1 structure (PDBID: 2BZH). 
Orange: Ensemble conformation docking of compound (R)-1 to the PIM1 ensemble of structures based on 
native PIM1 structure. Tan: Single conformation docking of compound (R)-1 to the non-native PIM1 
structure (PDBID: 1YXT). Pink: Ensemble conformation docking of compound (R)-1 to the ensemble of 
PIM1 structures based on non-native PIM1 structure. Red: Crystal structures (PDB ID: 2BZH). 
All predicted complex structures were superimposed against the native pose (2BZH), 
with the closest one from each docking task shown in Figure 5.6. We also listed the 
parameters of the critical hydrogen bond between the NH group of the inhibitor and 
GLU121 of the protein in Table 5.2. When single-conformation docking was used in 
combination with the exact protein structure (2BZH), not surprisingly, the results (blue 
structure) closely resemble the native pose present in the same crystal structure. However, 
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when the approximate protein structure (1YXT) was used, the single-conformation 
docking failed to correctly present the critical hydrogen bond in the native pose. In 
contrast, when ensemble docking was applied on either the exact or the approximate 
protein structure, reasonable bound conformations (orange and pink structures) with the 
proper hydrogen bond and consistent with the native pose were among the sampled poses. 
Table 5.2 Parameters of the hydrogen bond between the NH group of compound 1-R and the residue 
GLU121 in PIM1 for complex conformations in Figure 5.6. 
Structures Distance (Å) Angle ( Degrees) 
Red (Crystal Structure) 2.0 151.02 
Blue (native/single docking) 1.72 140.16 
Orange (native/ensemble docking) 1.76 137.39 
Tan (nonnative/single docking) 3.55 114.33 
Pink (nonnative/ensemble docking) 1.65 135.03 
 
To show how the ensemble of conformations provides a more suitable ligand docking 
environment, the 100 conformations of the PIM1 ensemble corresponding to non-native 
structure (PDBID: 1YXT) are aligned together and depicted in Figure 5.7 (A). It is 
evident that the snapshots in our ensemble simulations sample the kinase flexibility by 
exploring both backbone and side chain fluctuations around the crystallographic 
conformation used as the starting point for the MD simulations. In Figure 5.7 (B), the 
initial non-native PIM1 conformation (PDBID: 1YXT) and the conformation which binds 
the inhibitor with the lowest dock energy are aligned together and the key residues 
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around the binding pocket are depicted. The comparison reveals the shifting of key 
residues, in particular, GLU171, ASP128 and ASP186, from the initial non-native 
structure, and the rearrangement of the flexible Gly-rich loop (Gly45) to better position 
the CO group and the Cp ring.  
 
Figure 5.7 (A) Snapshots of PIM1 conformations generated from MD simulations based on the non-native 
PIM1 structure (PDBID: 1YXT). Snapshots are aligned by overall RMSD, and colored by atom types. The 
black conformation is the crystallized non-native PIM1 conformation. (B) Protein conformation 
comparison between the non-native crystallized structure of PIM1 (PDBID: 1YXT, gray) and the predicted 
protein bound conformation with the lowest RMSD to the reference structure using the ensemble 
conformation docking corresponding to this non-native PIM1 system (orange).  
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Figure 5.8 Top two ranks of conformations of compound (R/S)-1 bound to PIM1 predicted by ensemble 
docking. (A), (B): compound (R)-1. (C), (D): compound (S)-1. We denote the similar conformations in (A), 
(C) as conformation I and those in (B), (D) as conformation II. 
As we noted in Figure 5.6, the non-native PIM1 structure fails to account for the 
conserved hydrogen bond between GLU121:O – (R)-1:H1, which is captured after the 
slight rearrangement of active-site residues using the ensemble docking protocol. Thus, 
the implicit protein flexibility in our protocol yields a better docked score for this 
conformation. Even though protein kinases are known to assume multiple conformational 
states in a rugged energy landscape [94]  which are not exhaustively sampled in short 
MD simulations, we find that by sampling the fluctuations of protein conformation 
around a given initial state of our control system, our ensemble protocol demonstrates 
clear improvement in the prediction of the ligand-bound structure of the complex.  
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5.3.2 Two dominated conformations are predicted for (R/S)-1 to bind 
with GSK-3 and PIM-1 
 
Figure 5.9 Top two ranks of conformations of compound (R/S)-1 bound to GSK3-β predicted by ensemble 
docking. (A), (B): compound (R)-1. (C), (D): compound (S)-1. We denote the similar conformations in (A), 
(C) as conformation I and those in (B), (D) as conformation II. 
In Figure 5.5, we can see that for both the enantiomers, two conformations are predicted 
with relatively lower docking energies compared to other conformation, with RMSDs of 
2 Å and 5 Å from the crystallized conformation, respectively.  The two predicted 
structures for both enantiomers are depicted in Figure 5.8. In all of the conformations, the 
pyridocarbazole moiety forms a hydrogen bond between the maleimide NH group and the 
backbone carbonyl oxygen atom of residue within the hinge region (GLU 121) of the 
kinase, which mimics the hydrogen-bonding pattern of the ATP as well as staurosporine 
with the kinase, and is present in the PIM1/(R)-1 crystal structure. One of the two 
conformations, which we denote as conformation I (Figure 5.8 A and C), is very similar 
109 
 
to the reference structure constructed from crystallography. In the second conformation, 
which we denote as conformation II, the CO and Cp groups occupy opposite (swapped) 
positions relative to conformation I. Thus the two conformations I and II are related by a 
180 flip around an axis through the NH group of the pyridocarbazole moiety. The 
existence of conformation II as a stable structure has not been confirmed through 
crystallographic studies of the PIM1 kinase. However, this conformation is very close to 
a recent structure of compound (S)-2 bound to a lipid kinase (PI3K) [278]. Hence, we 
propose conformation II as a competing alternative bound conformation for the inhibitor 
bound to the protein kinase. 
The same two conformations of compound (R/S)-1 also turn out to be the most dominant 
bound conformation with GSK-3β through ensemble docking as depicted in Figure 5.8, 
making the binding characteristics of the (R/S)-1 Ru-compound with GSK-3β similar to 
those with PIM1. 
5.3.3 A unique bound conformation of the ruthenium compound 
dominates its binding to CDK2  
Our results for the bound conformations (R/S)-1 to CDK2/cyclin A are in stark contrast to 
those for PIM1 and GSK-3β. The conformation close to the two conformation for PIM1 
and GSK-3β are ranked lower (4th for (R)-1) or not present in our prediction ((S)-1). The 
disfavor of these two conformations is an evidence for unfavorable binding of this 
compound to CDK2/cyclin A in the native conformation observed in PIM1 and GSK-3β.  
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Figure 5.10 The top conformation predicted for both enantiomers bound to CDK2.  
While the conformations I and II are not favorable for CDK2, we found the top-ranked 
conformation for both enantiomers are very similar and this conformation is unique to 
CDK2, not PIM1 and GSK-3β.  In Figure 5.10, we depict the lowest-energy 
conformations predicted for CDK2/cyclin A. The lowest-rank conformations for both 
enantiomers are found to be quite similar, which strikingly, instead of forming a 
hydrogen bond with the hinge region residue, show that the NH group of the 
pyridocarbazole moiety points outside the binding pocket. Moreover, the plane of the Cp 
ring stacks with the plane of the aromatic PHE80, the gate-keeper residue. The CO group 
orients into the small binding pocket formed by ALA144, ASP145, ASN132 and 
GLN131. In this conformation, even though the compounds appear to fit nicely within 
the CDK2 binding site, there is the distinct lack of the conserved hydrogen bond, which 
warrants further investigation and experimental validation of the structure of the inhibitor 
complexed to CDK2. 
5.4 Discussion 
Based on in vitro protein kinases profiling results, it has been determined that the racemic 
mixture of ruthenium-based organometalic protein kinase inhibitor scaffold (compound 
111 
 
(R/S)-1) prefers to inhibit PIM1, GSK-3β over CDK2/cyclin A, even though the active 
sites of the three kinases show high degree of sequence and structure similarity. Here, we 
find that the ruthenium-based compounds bind in a similar fashion to PIM1 and GSK-3β 
but show a novel conformation with marked differences in binding to CDK2/cyclin A. 
Based on our structural analysis, we suggest the following reasons to explain this 
selectivity: (1) despite the extensive structure and sequence homology, CDK2 differs in 
the active site at the location of PHE80, which possibly stabilizes a novel bound 
confromation due to a stacking interaction with the Cp ring. This conformaiton also lacks 
the characteristic hydrogen bond between the inhibitor and linker region residue of the 
kinase and may cause a non-preference to the bound conformation. (2) Compared to 
PIM1 and GSK-3β, it is less preferrable for CDK2/cyclin A to bind the inhibitor 
(especially the S-isomer) in a conformation which preserves the conserved hydrogen 
bond. By aligning the CDK2 structure to PIM1 and GSK-3β, we suggest that residue 
PHE80 may  play a negative role in positioning the carboxyl group in the pyridocarbazole 
plane (Figure 5.2). We therefore suggest to examine the selectivity profile of compound 2 
shown in Figure 5.11 (C), which may help to further clarify the possible reason for the 
different binding of compound 1 with GSK-3β and CDK2.  
Using the existing crystal structure of PIM1/(R)-1 as a control test, we also have shown 
that by implicitly accounting for the protein flexibility, the ensemble docking protocol is 
able to help refine the structural features as well as discriminate the docked energies 
associated with bound conformations of two enantiomeric forms of the inhibitor to the 
three kinases. The comparison of results from single point docking and ensemble docking 
demonstrate that the traditional docking method based on a single protein conformation is 
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sensitive to the protein structure used. Although it generates good docking poses on the 
exact protein structure, the results become considerably worse on even a slightly different 
protein structure. The ensemble docking represents a significant improvement in this 
aspect, yielding consistent results regardless of the initial protein structure used. For the 
cases presented above, in which the native pose is unknown, the ensemble docking 
protocol is more robust and reliable in sampling the true complex structure. 
 
Figure 5.11 Structure of compound 1 (A), staurosporine (B) and the new compound 2 we proposed for 
further testing (C). 
In our ensemble docking analysis, we employ the lowest dock energy conformation to 
characterize the clusters and show that for PIM1 and GSK-3β, the ensemble docking 
protocol ranks the native-like conformations as one of the top clusters. Another popular 
choice for scoring the conformations is based on the frequency of an observed cluster 
[274]. In our case, we find that many of the top-ranked clusters based on the dock energy 
would also be identified by the high-frequency criterion. Hence the two criteria tend to 
yield similar predictions for the top-ranked conformations.  
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In the ensemble docking protocol we have employed, we do not consider the induced 
effect of the inhibitor to the protein conformation, i.e., our docking protocol only 
accounts for protein flexibility implicitly. Our assumption is that by sampling the protein 
kinase in and around its unbound (apo) state, the dynamics of the protein will account for 
the small induced effect and the bound conformations will select for those protein 
conformations resulting in lower dock scores. Thus for a good scoring function (with 
large correlation between experimental binding affinity and the computed docking score 
on an extensive test set of compounds), the ensemble docking is expected to yield 
conformations with the lowest binding affinities. We advocate that our ensemble docking 
approach is a good first step in cases where we have some knowledge of the protein 
structure (through experimental or modeling schemes), such as the prediction of the 
bound complex with a new inhibitor scaffold.  
We also note the organometalic inhibitor compounds we have studied are very new and 
fully flexible force-fields for these inhibitors are not yet available. Therefore, our focus in 
this chapter is on the structure prediction of the bound complex as opposed to the free 
energy of binding. Once the structural aspects are validated, our predictions are then 
logical candidates for a more rigorous evaluation using computationally intensive free 
energy protocols in fully atomistic systems [102, 150, 153, 204, 239]. 
Chapter 6 Perspectives and Future Directions 
In this thesis, we developed and applied several computational tools at multiple length 
and time scales to model the interaction inhibitors with protein kinases and the catalytic 
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reaction mechanism of protein kinases. Our work on EGFR TKD, sheds insight on the 
unique properties of this important kinase. Moreover, our understanding of the EGFR 
kinase also helps in delineating common mechanisms across the whole protein kinase 
family.  
In Chapter 2, we predicted how the EGFR TKD recognizes its substrates and performed 
the catalytic phosphoryl transfer reaction using a computational protocol combining 
molecular dynamics simulations, ensemble molecular docking [161, 274], free energy 
calculation[102, 117, 150, 153, 231, 253, 266] and QM/MM. We found that in our 
predicted bound conformations the P-1 glutamic acid residue and the hydrophobic amino 
acid at the P+1 position interact with a highly conserved motif in the protein kinase 
family, namely Val852-Pro853-Ile854-Lys855-Trp856 in EGFR. This motif creates a 
binding surface to form hydrophobic contacts as well as hydrogen bonds to residues close 
to P-site (P0) tyrosine in the substrate and therefore helps to orient the tyrosine residue 
towards the active site. Moreover, our QM/MM simulations show that the EGFR protein 
kinase favors the dissociative mechanism, although an alternative channel through the 
formation of an associative transition state is also possible. Collectively, our simulations 
establish some key molecular rules in operation for the substrate-binding and catalytic 
landscapes in the EGFR TKD. 
A possible future direction is to extend this work to understanding how mutations affect 
substrate binding. The kinase-activating mutation L834R closely locates to the catalytic 
site. Based on our simulation results of how EGFR TKD recognize its substrate 
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sequences, we are able to further investigate whether mutating the hydrophobic residue 
LEU to a positively charged residue ARG will affect the peptide binding affinity.  
 
Figure 6.1 Cumulative free energy (kcal/mol) calculated for bound and unbound systems. 
In our preliminary studies, we employ the free energy perturbation (FEP) method to 
calculate the binding free energy difference between the wildtype and mutant systems for 
peptide Y1068. The FEP results (Figure 6.1 and Table 6.1) showed that L834R mutation 
resulted in a binding free energy change (F) of 4.26 ± 4.2 kcal/mol. Our results imply 
that the mutation does not increase (but rather decreases) the substrate binding affinity of 
the particular peptide. Moreover, by comparing how L834R will alter the binding of 
different substrates (Y1068 and Y1173 for example), we can further gain insight on the 
effect of this point mutation to differential signaling pathways.  
Another promising avenue is to explore the roles of L834R on EGFR kinase catalysis. 
Experimental data has shown that the value of the catalytic efficiency (kcat/KM) for the 
L834R mutant is ~20-fold higher than that for the wild-type kinase domain [289]. 
Although the mutated residue in the L834R mutant is not directly involved in the 
116 
 
catalytic mechanism, we proposed that the residue is very close to reaction site, three 
amino acids displaced from D831, which is critical to catalysis. Moreover, the 
phosphoryl transfer reaction is highly sensitive to the electrostatic environment. A 
mutation from a neutral residue to a highly positively charged residue close the reaction 
area may affect the reaction mechanism, which is a topic of significant interest.  
Table 6.1 Cumulative free energy (kcal/mol) calculated for bound and unbound systems. The error bar of 
our current calculation is about 4.2kcal/mol 
 
ΔG ΔΔG 
 
With peptide No peptide 
 
Forward 47.188 43.247 3.941 
Backward 43.3 38.716 4.584 
 
Moreover, the ErbB family of receptors has four members ― the epidermal growth factor 
receptor (EGFR or ErbB1 or HER1), ErbB2 (or HER2), ErbB3, and ErbB4. They share 
high sequence homology and a common protein structure. Among all the members, 
ErbB3/HER3 stands out among the mammalian ErbB receptors since it is generally 
considered to be kinase-inactive [62] because a conserved aspartate that is thought to 
function as a catalytic base in all protein kinases [167] – deprotonating the substrate 
hydroxyl group – is replaced by an asparagine in ErbB3 (N815). HER2, on the other 
hand, is thought to be an orphan receptor, with none of the EGF family of ligands able to 
activate it. ErbB2 and ErbB3 can only be activated through heterodimerization [18, 62], 
and neuregulin-induced ErbB2/ErbB3 heterodimers are considered to be the most potent 
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mitogenic signaling complexes in the ErbB receptor network [62, 116]. This presents a 
conundrum given current models for ErbB receptor kinase activation, in which one 
kinase domain allosterically activates its neighbor and becomes trans-autophosphorylated 
as a consequence [140, 287]. In such a mechanism, it is not clear how ErbB2 could be 
trans-phosphorylated within an ErbB2/ErbB3 heterodimer unless ErbB3 does have 
kinase activity. Our previous work, collaborating with Dr. Mark Lemmon‟s group on 
ErbB3 (see Chapter 2), proposed a mechanism for ErbB3 to catalyze the phosphryl 
transfer reaction. A further study on the catalysis of ErbB2 and ErbB4 could to gain more 
insight on functional and mechanistic inter-relationships among the family members in 
controlling substrate activation and signaling.  
Finally, our studies on erlotinib (Chapter 3) showed that the L834R does not change the 
binding affinity of erlotinib to EGFR TKD in the active state. We further extended our 
study to understand how the erlotinib interacts with inactive EGFR TKD. Our simulation 
results proposed the possible binding of erlotinib to both active and inactive state of the 
kinase. Our collaborator, Dr. Mark Lemmon‟s group, is working on crystallizing the 
complex between erlotinib and inactive EGFR TKD. Further investigation of inhibitor-
bound conformations of the EGFR kinase may illuminate the concept that erlotinib is 
effective at inhibiting the ligand-activated EGFR kinase and it may also help to 
investigate new compound to inhibit EGFR TKD. This is a promising prospect as it 
allows us to target inactive and alternative conformations of kinases for inhibition. Even 
though structures of active conformations of several kinases are structurally homologous, 
there seems to be a greater variation in the structures of inactive and intermediate forms. 
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Thus, the strategy to target conformations different from the active state opens new 
possibilities in designing specific kinase inhibitors for cancer therapy. 
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